SARS-CoV-2 evolution during treatment of chronic infection

2

1

- 3 Steven A Kemp¹*, Dami A Collier ^{1,2,3}*, Rawlings P Datir^{*2,3}, Isabella ATM Ferreira ^{2,3}, Salma
- 4 Gayed⁴, Aminu Jahun⁵, Myra Hosmillo⁵, Chloe Rees-Spear¹, Petra Mlcochova ^{2,3}, Ines Ushiro
- 5 Lumb⁶, David J Roberts⁶, Anita Chandra^{2,3}, Nigel Temperton⁷, The CITIID-NIHR BioResource
- 6 COVID-19 Collaboration°, The COVID-19 Genomics UK (COG-UK) Consortium°°, Katherine
- 7 Sharrocks K⁴, Elizabeth Blane³, Yorgo Modis⁸, Kendra Leigh⁸, John Briggs⁸, Marit van Gils⁹,
- 8 Kenneth GC Smith^{2,3}, John R Bradley^{3,10}, Chris Smith¹¹, Rainer Doffinger¹³, Lourdes Ceron-
- 9 Gutierrez¹³, Gabriela Barcenas-Morales^{13,14}, David D Pollock¹⁵, Richard A Goldstein¹, Anna
- 10 Smielewska ^{5,11}, Jordan P Skittrall ^{4,12,16}, Theodore Gouliouris ⁴, Ian G Goodfellow⁵, Effrossyni
- Gkrania-Klotsas⁴, Christopher JR Illingworth^{12,17}, Laura E McCoy¹, Ravindra K Gupta^{2,3,18}

- 13 ¹Division of Infection and Immunity, University College London, London, UK.
- ² Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
- 15 ³Department of Medicine, University of Cambridge, Cambridge, UK.
- ⁴Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust,
- 17 Cambridge, UK.
- 18 ⁵Department of Pathology, University of Cambridge, Cambridge
- 6 NHS Blood and Transplant, Oxford and BRC Haematology Theme, University of Oxford, UK
- ⁷Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK
- ⁸Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.
- ⁹Department of Medical Microbiology, Academic Medical Center, University of Amsterdam,
- 23 Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands
- 24 ¹⁰ NIHR Cambridge Clinical Research Facility, Cambridge, UK.
- 25 ¹¹Department of Virology, Cambridge University NHS Hospitals Foundation Trust
- ¹²Department of Applied Mathematics and Theoretical Physics, University of Cambridge, UK
- 27 ¹³ Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital
- 28 ¹⁴ FES-Cuautitlán, UNAM, Mexico

29	¹⁵ Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora,
30	Colorado, USA;
31	¹⁶ Clinical Microbiology and Public Health Laboratory, Addenbrookes' Hospital, Cambridge, UK
32	¹⁷ MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
33	¹⁸ Africa Health Research Institute, Durban, South Africa
34	
35	°The CITIID-NIHR BioResource COVID-19 Collaboration, see appendix for author list
36	$^{\circ\circ}$ The COVID-19 Genomics UK (COG-UK) Consortium, see appendix for author list
37	
38	*equal contribution
39	
40	Address for correspondence:
41	Ravindra K. Gupta
42	Cambridge Institute for Therapeutic Immunology and Infectious Diseases
43	Jeffrey Cheah Biomedical Centre
44	Puddicombe Way
45	Cambridge CB2 0AW, UK
46	Tel: +44 1223 331491
47	rkg20@cam.ac.uk
48	
49	Key words: SARS-CoV-2; COVID-19; antibody escape, Convalescent plasma; neutralising
50	antibodies; mutation; evasion; resistance; immune suppression
51	
52	Summary
53	SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2 ¹ , and is a major
54	antibody target. Here we report chronic SARS-CoV-2 with reduced sensitivity to neutralising
55	antibodies in an immune suppressed individual treated with convalescent plasma, generating
56	whole genome ultradeep sequences over 23 time points spanning 101 days. Little change was
57	observed in the overall viral population structure following two courses of remdesivir over the

first 57 days. However, following convalescent plasma therapy we observed large, dynamic virus population shifts, with the emergence of a dominant viral strain bearing D796H in S2 and Δ H69/ Δ V70 in the S1 N-terminal domain NTD of the Spike protein. As passively transferred serum antibodies diminished, viruses with the escape genotype diminished in frequency, before returning during a final, unsuccessful course of convalescent plasma. *In vitro*, the Spike escape double mutant bearing Δ H69/ Δ V70 and D796H conferred modestly decreased sensitivity to convalescent plasma, whilst maintaining infectivity similar to wild type. D796H appeared to be the main contributor to decreased susceptibility but incurred an infectivity defect. The Δ H69/ Δ V70 single mutant had two-fold higher infectivity compared to wild type, possibly compensating for the reduced infectivity of D796H. These data reveal strong selection on SARS-CoV-2 during convalescent plasma therapy associated with emergence of viral variants with evidence of reduced susceptibility to neutralising antibodies.

Clinical case history of SARS-CoV-2 infection in setting of immune-compromised host

A septuagenarian male was admitted to a tertiary hospital in summer of 2020 and had tested positive for SARS-CoV-2 RT-PCR 35 days previously on a nasopharyngeal swab (Day 1) at a local hospital (Extended data 1 and 2). His past medical history was significant for marginal B cell lymphoma diagnosed in 2012, with previous chemotherapy including vincristine, prednisolone, cyclophosphamide and anti-CD20 B cell depletion with rituximab. It is likely that both chemotherapy and underlying lymphoma contributed to B and T cell combined immunodeficiency (Extended data 2 and 3, Supplementary Table 1). Computed tomography (CT) of the chest showed widespread abnormalities consistent with COVID-19 pneumonia (Supplementary Figure 1). Treatment included two 10-day courses of remdesivir with a five day gap in between (Extended data 1). Two units of convalescent plasma were administered on days 63 and 65 (Extended data 3). Following clinical deterioration, remdesivir and a unit of convalescent plasma were administered on day 95, but the individual unfortunately died on day 102 (Supplementary text).

Virus genomic comparative analysis of 23 sequential respiratory samples over 101 days

The majority of samples were respiratory samples from nose and throat or endotracheal aspirates during the period of intubation (Supplementary Table 3). Ct values ranged from 16-34 and all 23 respiratory samples were successfully sequenced by standard single molecule sequencing approach as per the ARTIC protocol implemented by COG-UK; of these 20 additionally underwent short-read deep sequencing using the Illumina platform (Supplementary table 4). There was general agreement between the two methods (Extended data 4). However due to the higher reliability of Illumina for low frequency variants, this was used for formal analysis^{2,3}. Additionally, single genome amplification and sequencing of Spike using extracted RNA from respiratory samples was used as an independent method to detect mutations observed (Extended data 4). Finally, we detected no evidence of recombination, based on two independent methods.

Maximum likelihood analysis of patient-derived whole genome consensus sequences demonstrated clustering with other local sequences from the same region (Figure 1). The infecting strain was assigned to lineage 20B bearing the D614G Spike variant. Environmental sampling showed evidence of virus on surfaces such as telephone and call bell. Sequencing of these surface viruses showed clustering with those derived from the respiratory tract (Extended data 2). All samples were consistent with having arisen from a single underlying viral population. In our phylogenetic analysis, we included sequential sequences from three other local patients identified with persistent viral RNA shedding over a period of 4 weeks or more as well as two long term immunosuppressed SARS-CoV-2 'shedders' recently reported^{4,5}, (Extended data 2, Supplementary Table 2). While the sequences from the three local patients as well as from Avanzato et al⁵ showed little divergence with no amino acid changes in Spike over time, the case patient showed significant diversification. The Choi et al report⁴ showed similar degree of diversification as the case patient. Further investigation of the sequence data suggested the existence of an underlying structure to the viral population in our patient, with samples collected at days 93 and 95 being rooted within, but significantly divergent from the original population (Extended data 5 and 6). The relationship of the divergent samples to those at earlier time points argues against superinfection.

SARS-CoV-2 viral diversity

All samples tested positive by RT-PCR and there was no sustained change in Ct values throughout the 101 days following the first two courses of remdesivir (days 41 and 54), or the first two units of convalescent plasma with polyclonal antibodies (days 63 and 65, Extended data 3). Of note we were not able to culture virus from stored swab samples. Consensus sequences from short read deep sequence Illumina data revealed dynamic population changes after day 65, as shown by a highlighter plot (Extended data 6). In addition, we were also able to follow the dynamics of virus populations down to low frequencies during the entire period (Figure 2, Supplementary Table 4). Following remdesivir at day 41 the low frequency variant analysis allowed us to observe transient amino acid changes in populations at below 50% abundance in Orf 1b, 3a and Spike, with a T39I (C27509T) mutation in ORF7a reaching 79% on day 45 (Figure 2, pink, supplementary information). At day 66 we noted I513T in NSP2 (T2343C) and V157L (G13936T) in RdRp had emerged from undetectable at day 54 to almost 100% frequency (Figure 2, red and green dashed lines), with the polymerase being the more plausible candidate for driving this sweep. Notably, spike variant N501Y, which can increase the ACE2 receptor affinity⁶, and which is present in the new UK B1.1.7 lineage⁷, was observed on day 55 at 33% frequency, but was eliminated by the sweep of the NSP2/RdRp variant.

In contrast to the early period of infection, between days 66 and 82, following the first two administrations of convalescent sera, a shift in the virus population was observed, with a variant bearing D796H in S2 and Δ H69/ Δ V70 in the S1 N-terminal domain (NTD) becoming the dominant population at day 82. This was identified in a nose and throat swab sample with high viral load as indicated by Ct of 23 (Figure 3A). The deletion was detected transiently at baseline according to short read deep sequencing. Δ H69/ Δ V70 was due to an out of frame six nucleotide deletion resulting in the sequence of codon 68 changing from ATA to ATC.

On Days 86 and 89, viruses obtained from upper respiratory tract samples were characterised by the Spike mutations Y200H and T240I, with the deletion/mutation pair observed on day 82

having fallen to frequencies of 10% or less (Figure 2 and 3). The Spike mutations Y200H and T240I were accompanied at high frequency by two other non-synonymous variants with similar allele frequencies, coding for I513T in NSP2, V157L in RdRp and N177S in NSP15 (Figure 2A). Both of these were also previously observed at >98% frequency in the sample on day 66 (Figure 2A, red and green lines), arguing that this new lineage emerged out of a previously existing population.

Sequencing of a nose and throat swab sample at day 93 identified viruses characterised by Spike mutations P330S at the edge of the RBD and W64G in S1 NTD at close to 100% abundance, with D796H along with Δ H69/ Δ V70 at <1% abundance and the variants Y200H and T240I at frequencies of <2%. Viruses with the P330S variant were detected in two independent samples from different sampling sites, arguing against the possibility of contamination. The divergence of these samples from the remainder of the population (Figure 2, 3B and Extended data 5 and 6) suggests the possibility that they represent a compartmentalised subpopulation.

Patterns in the variant frequencies suggest competition between virus populations carrying different mutations, viruses with the D796H/ΔH69/ΔV70 deletion/mutation pair rising to high frequency during CP therapy, then being outcompeted by another population in the absence of therapy. Specifically, these data are consistent with a lineage of viruses with the NSP2 I513T and RdRp V157L variant, dominant on day 66, being outcompeted during therapy by the mutation/deletion variant. With the lapse in therapy, the original strain, having acquired NSP15 N1773S and the Spike mutations Y200H and T240I, regained dominance, followed by the emergence of a separate population with the W64G and P330S mutations.

In a final attempt to reduce the viral load, a third course of remdesivir (day 93) and third dose of CP (day 95) were administered. We observed a re-emergence of the D796H + Δ H69/ Δ V70 viral population (Figure 2, 3). The inferred linkage of D796H and Δ H69/ Δ V70 was maintained as evidenced by the highly similar frequencies of the two variants, suggesting that the third unit of CP led to the re-emergence of this population under renewed positive selection. In further

support of our proposed idea of competition, noted above, frequencies of these two variants appeared to mirror changes in the NSP2 I513T mutation (Figure 2), suggesting these as markers of opposing clades in the viral population. Ct values remained low throughout this period with hyperinflammation, eventually leading to multi-organ failure and death at day 102. The repeated increase in frequency of the viral population with CP therapy strongly supports the hypothesis that the deletion/mutation combination conferred selective advantage.

Spike mutants emerging post convalescent plasma impair neutralising antibody potency

Using lentiviral pseudotyping we generated wild type, $\Delta H69/\Delta V70 + D796H$ and single mutant Spike proteins in enveloped virions in order to measure neutralisation activity of CP against these viruses (Figure 4). This system has been shown to give generally similar results to replication competent virus^{8,9}. Spike protein from each mutant was detected in pelleted virions (Figure 4A). We also probed with an HIV-1 p24 antibody to monitor levels of lentiviral particle production (Figure 4A, Supplementary Figure 2). We then measured infectivity of the pseudoviruses, correcting for virus input using reverse transcriptase activity measurement, and found that $\Delta H69/\Delta V70$ appeared to have two-fold higher infectivity over a single round of infection compared to wild type (Figure 4B, Extended data 7). By contrast, the D796H single mutant had significantly lower infectivity as compared to wild type and double mutant had similar infectivity to wild type (Figure 4B, Extended data 7).

We found that D796H alone and the D796H + Δ H69/ Δ V70 double mutant were less sensitive to neutralisation by convalescent plasma samples (Figure 4C-E, Extended data 7). By contrast the Δ H69/ Δ V70 single mutant did not reduce neutralisation sensitivity. In addition, patient derived serum from days 64 and 66 (one day either side of CP2 infusion) similarly showed lower potency against the D796H + Δ H69/ Δ V70 mutants (Figure 4F, G).

A panel of nineteen monoclonal antibodies (mAbs) isolated from three donors was previously identified to neutralize SARS-CoV-2. To establish if the mutations incurring *in vivo* (D796H and Δ H69/ Δ V70) resulted in a global change in neutralization sensitivity we tested neutralising mAbs

targeting the seven major epitope clusters previously described (excluding non-neutralising clusters II, V and small [n =<2] neutralising clusters IV, X). The eight RBD-specific mAbs (Extended data 8) exhibited no major change in neutralisation potency and non-RBD specific COVA1-21 showing 3-5 fold reduction in potency against Δ H69/ Δ V70+D796H and Δ H69/ Δ V70, but not D796H alone⁹ (Extended data 8). We observed no differences in neutralisation between single/double mutants and wild type, suggesting that the mechanism of escape was likely outside these epitopes in the RBD. These data confirm the specificity of the findings from convalescent plasma and suggest that mutations observed are related to antibodies targeting regions outside the RBD. Interestingly , Δ H69/ Δ V70 containing viruses showed reduced neutralisation sensitivity to the mAb COVA1-21, targeting an as yet undefined epitope outside the RBD. ¹⁰.

To understand how the Δ H69/ Δ V70 and D796H might confer antibody resistance, we assessed how they might affect the Spike structure (Extended data 9). We based this analysis primarily on a structure lacking stabilising modifications (PDB 6xr8)¹¹, but also referred to stabilised structures determined at different pH values¹². Δ H69/ Δ V70 is located in a disordered, glycosylated loop at the distal surface of the NTD, near the binding site of polyclonal antibodies derived from COV57 plasma^{13,14} (Extended data 9). As this loop is flexible and highly accessible, Δ H69/V70 could in principle affect antibody binding in this region. D796 is located near the base of Spike, in a surface loop that is structurally somewhat disordered in the prefusion conformation and becomes part of a large disordered region in the post fusion S2 trimer¹¹ (Extended data 9). The loop containing residue 796 is proposed to be targeted by antibodies¹⁵, despite mutations at position 796 being relatively uncommon (Extended data 9). In the RBD-down Spike structures^{11,12}, D796 forms contacts with residues in the neighbouring protomer, including the glycosylated residue N709 (Extended data 9).

Discussion

Here we have documented a repeated evolutionary response by SARS-CoV-2 in the presence of antibody therapy during the course of a persistent infection in an immunocompromised host.

The observation of potential selection for specific variants coinciding with the presence of antibodies from convalescent plasma is supported by the experimental finding of two-fold reduced susceptibility of these viruses to convalescent plasma containing polyclonal antibodies. In this case the emergence of the variant was not the primary reason for treatment failure.

We have noted in our analysis signs of compartmentalised viral replication based on the sequences recovered in upper respiratory tract samples. Both population genetic and small animal studies have shown a lack of reassortment between influenza viruses within a single host during an infection, suggesting that acute respiratory viral infection may be characterised by spatially distinct viral populations^{16,17}. In the analysis of data, it is important to distinguish genetic changes which occur in the primary viral population from apparent changes that arise from the stochastic observation of spatially distinct subpopulations in the host. While the samples we observe on days 93 and 95 of infection are genetically distinct from the others, the remaining samples are consistent with arising from a consistent viral population. We note that Choi et al reported the detection in post-mortem tissue of viral RNA not only in lung tissue, but also in the spleen, liver, and heart⁴. Mixing of virus from different compartments, for example via blood, or movement of secretions from lower to upper respiratory tract, could lead to fluctuations in viral populations at particular sampling sites.

This is a single case report and therefore limited conclusions can be drawn about generalisability.

An important limitation is that the data were derived from sampling from the upper respiratory tract and not the lower tract, thus limiting the inferences that can be drawn regarding viral populations in this single case.

In addition to documenting the emergence of SARS-CoV-2 Spike Δ H69/ Δ V70 *in vivo*, we show that this mutation modestly increases infectivity of the Spike protein in a pseudotyping assay. The deletion was observed contemporaneously with the rare S2 mutation D796H after two separate courses of CP, with other viral populations emerging. D796H, but not Δ H69/ Δ V70, conferred reduction in susceptibility to polyclonal antibodies in the units of CP administered,

though we cannot speculate as to their individual impacts on sera from other individuals. It is intriguing that the Δ H69/ Δ V70 + D796H double mutant diminished in between CP courses, suggesting that there were other selective forces at play in the intervening period, possibly driven by the inflammation observed in the individual. This includes the possibility that the haplotype with Δ H69/ Δ V70 + D796H may have carried mutations in other regions deleterious during that intervening period. Although Δ H69/V70 is expanding at a high rate¹⁸, D796 mutations are also increasing. D796H has been documented in 0.02% of global sequences and D796Y appears in 0.05% of global sequences (Extended data 9).

The effects of CP on virus evolution seen here are unlikely to apply in immune competent hosts where viral diversity is likely to be lower due to better immune control. Our data highlight that infection control measures may need to be tailored to the needs of immunocompromised patients and also caution in interpretation of CDC guidelines that recommend 20 days as the upper limit of infection prevention precautions in immune compromised patients who are afebrile¹⁹. Due to the difficulty with culturing clinical isolates, use of surrogates are warranted²⁰. However, where detection of ongoing viral evolution is possible, this serves as a clear proxy for the existence of infectious virus. In our case we detected environmental contamination whilst in a single occupancy room and the patient was moved to a negative-pressure high air-change infectious disease isolation room.

Clinical efficacy of convalescent plasma in severe COVID-19 has not been demonstrated²¹, and its use in different stages of infection and disease remains experimental; as such, we suggest that it should be reserved for use within clinical trials, with rigorous monitoring of clinical and virological parameters. The data from this single case report might warrant caution in use of convalescent plasma in patients with immune suppression of both T cell and B cell arms; in such cases, the antibodies administered have little support from cytotoxic T cells, thereby reducing chances of clearance and theoretically raising the potential for escape mutations. Whilst we await further data, where clinical trial enrolment is not possible, convalescent plasma administered for clinical need in immune suppression should ideally only be considered as part

of observational studies, undertaken preferably in single occupancy rooms with enhanced infection control precautions, including SARS-CoV-2 environmental sampling and real-time sequencing. Understanding of viral dynamics and characterisation of viral evolution in response to different selection pressures in the immunocompromised host is necessary not only for improved patient management but also for public health benefit.

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

290

291

292

293

294

Acknowledgements

We are immensely grateful to the patient and his family. We would also like to thank the staff at CUH and the NIHR Cambridge Clinical Research Facility. We would like to thank Dr Ruthiran Kugathasan and Professor Wendy Barclay for helpful discussions and Dr Martin Curran, Dr William Hamilton, and Dr. Dominic Sparkes. We would like to thank Prof Andres Floto and Prof Ferdia Gallagher. We thank Dr James Voss for the kind gift of HeLa cells stably expressing ACE2. We would like to thank James Nathan for RBD protein and Leo James for N protein. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. RKG is supported by a Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA). LEM is supported by a Medical Research Council Career Development Award (MR/R008698/1). SAK is supported by the Bill and Melinda Gates Foundation via PANGEA grant: OPP1175094. DAC is supported by a Wellcome Trust Clinical PhD Research Fellowship. CJRI acknowledges MRC funding (ref: MC UU 00002/11). This research was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, the Cambridge Clinical Trials Unit (CCTU) and by the UCL Coronavirus Response Fund and made possible through generous donations from UCL's supporters, alumni, and friends (LEM). JAGB is supported by the Medical Research Council (MC UP 1201/16). IG is a Wellcome Senior Fellow and supported by the Wellcome Trust (207498/Z/17/Z). DDP is supported by NIH GM083127.

316317

Competing interests: the authors declare no competing interests

- 319 **Ethics**
- 320 The study was approved by the East of England Cambridge Central Research Ethics Committee
- 321 (17/EE/0025). Written informed consent was obtained from both the patient and family.
- 322 Additional controls with COVID-19 were enrolled to the NIHR BioResource Centre Cambridge
- 323 under ethics review board (17/EE/0025).

325

- Author contributions
- 326 Conceived study: RKG, SAK, DAC, AS, TG, EGK
- Designed experiments: RKG, SAK, DAC, LEM, JAGB, EGK, AC, NT, AC, CS, RD, RG, DDP, YM
- 328 Performed experiments: SAK, DAC, LEM, RD, CRS, AJ, IATMF, KS, TG, CJRI, BB, JS, MJvG, LGC,
- 329 GBM, LK
- 330 Interpreted data: RKG, SAK, DAC, PM, LEM, JAGB, PM, SG, KS, TG, JB, KGCS, IG, CJRI, JAGB, IUL,
- 331 DR, JS, BB, RAG. DDP, RD, LCG, GBM

332

- References
- 334 1 Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a
- 335 Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278, doi:10.1016/j.cell.2020.02.052
- 336 (2020).
- 337 2 Kim, K. W. et al. Respiratory viral co-infections among SARS-CoV-2 cases confirmed by virome
- 338 capture sequencing. (2020).
- 339 3 Bull, R. A. et al. Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome
- 340 analysis. *Nat Commun* **11**, 6272, doi:10.1038/s41467-020-20075-6 (2020).
- 341 4 Choi, B. et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. The
- 342 New England journal of medicine **383**, 2291-2293, doi:10.1056/NEJMc2031364 (2020).
- 343 5 Avanzato, V. A. et al. Case Study: Prolonged infectious SARS-CoV-2 shedding from an
- 344 asymptomatic immunocompromised cancer patient. *Cell* (2020).
- 345 6 Starr, T. N. et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals
- 346 Constraints on Folding and ACE2 Binding. Cell 182, 1295-1310 e1220,
- 347 doi:10.1016/j.cell.2020.08.012 (2020).
- Rambaut A., L. N., Pybus O, Barclay W, Carabelli A. C., Connor T., Peacock T., Robertson D. L.,
- Volz E., on behalf of COVID-19 Genomics Consortium UK (CoG-UK). Preliminary genomic

- characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations, https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563 (2020).

 Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and
- Schmidt, F. *et al.* Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. 2020.2006.2008.140871, doi:10.1101/2020.06.08.140871 %J bioRxiv (2020).
- Brouwer, P. J. M. *et al.* Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. *Science* **369**, 643-650, doi:10.1126/science.abc5902 (2020).
- Zussman, M. E., Bagby, M., Benson, D. W., Gupta, R. & Hirsch, R. Pulmonary vascular resistance in repaired congenital diaphragmatic hernia vs. age-matched controls. *Pediatr Res* **71**, 697-700, doi:10.1038/pr.2012.16 (2012).
- 360 11 Cai, Y. *et al.* Distinct conformational states of SARS-CoV-2 spike protein. *Science*, doi:10.1126/science.abd4251 (2020).
- 362 12 Zhou, T. *et al.* Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-363 Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. *Cell Host & Microbe* 28, 867-879.e865, doi:10.1016/j.chom.2020.11.004 (2020).
- 365 13 Robbiani, D. F. *et al.* Convergent antibody responses to SARS-CoV-2 in convalescent individuals.

 366 *Nature* **584**, 437-442, doi:10.1038/s41586-020-2456-9 (2020).
- 367 14 Barnes, C. O. et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common 368 of Antibodies. **Epitopes** and Recurrent Features Cell 182, 828-842 e816, 369 doi:10.1016/j.cell.2020.06.025 (2020).
- 370 Shrock, E. *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. *Science*, doi:10.1126/science.abd4250 (2020).
- 372 Sobel Leonard, A. *et al.* The effective rate of influenza reassortment is limited during human infection. *PLoS Pathog* **13**, e1006203, doi:10.1371/journal.ppat.1006203 (2017).
- 374 17 Richard, M., Herfst, S., Tao, H., Jacobs, N. T. & Lowen, A. C. Influenza A Virus Reassortment Is 375 Limited by Anatomical Compartmentalization following Coinfection via Distinct Routes. *J Virol* 376 **92**, doi:10.1128/JVI.02063-17 (2018).
- 377 18 Kemp, S. *et al.* Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion H69/V70.

 378 *bioRxiv*, 2020.2012.2014.422555, doi:10.1101/2020.12.14.422555 (2021).
- 379 CDC. Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-380 19 in Healthcare Settings (Interim Guidance), https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html (2020).

- Boshier, F. A. T. *et al.* Remdesivir induced viral RNA and subgenomic RNA suppression, and evolution of viral variants in SARS-CoV-2 infected patients. *medRxiv*, 2020.2011.2018.20230599,
- 384 doi:10.1101/2020.11.18.20230599 (2020).
- 385 21 Simonovich, V. A. et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe
- 386 Pneumonia. *N Engl J Med*, doi:10.1056/NEJMoa2031304 (2020).
- 387 22 Meredith, L. W. et al. Rapid implementation of SARS-CoV-2 sequencing to investigate cases of
- health-care associated COVID-19: a prospective genomic surveillance study. The Lancet
- 389 *Infectious Diseases* **20**, 1263-1272, doi:10.1016/S1473-3099(20)30562-4 (2020).
- 390 23 Collier, D. A. et al. Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A
- 391 Clinical Validation Trial and Implementation Study. Cell Rep Med, 100062,
- 392 doi:10.1016/j.xcrm.2020.100062 (2020).
- 393 24 Loman, N., Rowe, W. & Rambaut, A. (v1, 2020).
- 394 25 Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
- 395 *EMBnet. journal* **17**, 10-12 (2011).
- 396 26 Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics (Oxford, England)*
- 397 **34**, 3094-3100, doi:10.1093/bioinformatics/bty191 (2018).
- 398 27 Jordan, M. R. et al. Comparison of standard PCR/cloning to single genome sequencing for
- analysis of HIV-1 populations. *J Virol Methods* **168**, 114-120, doi:10.1016/j.jviromet.2010.04.030
- 400 (2010).
- 401 28 Palmer, S. et al. Multiple, linked human immunodeficiency virus type 1 drug resistance
- 402 mutations in treatment-experienced patients are missed by standard genotype analysis. *Journal*
- 403 of clinical microbiology **43**, 406-413, doi:10.1128/JCM.43.1.406-413.2005 (2005).
- 404 29 Keele, B. F. et al. Identification and characterization of transmitted and early founder virus
- 405 envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the
- 406 *United States of America* **105**, 7552-7557 (2008).
- 407 30 Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data from vision to
- reality. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European
- 409 *communicable disease bulletin* **22**, 30494, doi:10.2807/1560-7917.ES.2017.22.13.30494 (2017).
- 410 31 Katoh, K. & Standley, D. M. MAFFT Multiple Sequence Alignment Software Version 7:
- Improvements in Performance and Usability. *Molecular Biology and Evolution* **30**, 772-780,
- 412 doi:10.1093/molbev/mst010 (2013).

- Rambaut, A. *et al.* A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic
- 414 epidemiology. *Nature Microbiology* **5**, 1403-1407, doi:10.1038/s41564-020-0770-5 (2020).
- 415 33 Minh, B. Q. et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in
- the Genomic Era. *Molecular Biology and Evolution* **37**, 1530-1534, doi:10.1093/molbev/msaa015
- 417 (2020).
- 418 34 Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. & Jermiin, L. S. ModelFinder:
- fast model selection for accurate phylogenetic estimates. *Nature Methods* **14**, 587-589,
- 420 doi:10.1038/nmeth.4285 (2017).
- 421 35 Minh, B. Q., Nguyen, M. A. & von Haeseler, A. Ultrafast approximation for phylogenetic
- 422 bootstrap. *Mol Biol Evol* **30**, 1188-1195, doi:10.1093/molbev/mst024 (2013).
- 423 36 Illingworth, C. J. SAMFIRE: multi-locus variant calling for time-resolved sequence data.
- 424 *Bioinformatics* **32**, 2208-2209, doi:10.1093/bioinformatics/btw205 (2016).
- 425 37 Lumby, C. K., Zhao, L., Breuer, J. & Illingworth, C. J. A large effective population size for
- established within-host influenza virus infection. *Elife* **9**, doi:10.7554/eLife.56915 (2020).
- 427 38 Martin, D. P., Murrell, B., Golden, M., Khoosal, A. & Muhire, B. RDP4: Detection and analysis of
- recombination patterns in virus genomes. *Virus evolution* **1** (2015).
- 429 39 Didelot, X. & Wilson, D. J. ClonalFrameML: efficient inference of recombination in whole
- 430 bacterial genomes. *PLoS Comput Biol* **11**, e1004041 (2015).
- Wrobel, A. G. et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus
- evolution and furin-cleavage effects. *Nature Structural & Molecular Biology* **27**, 763-767,
- 433 doi:10.1038/s41594-020-0468-7 (2020).
- 434 41 Gregson, J. et al. HIV-1 viral load is elevated in individuals with reverse transcriptase mutation
- 435 M184V/I during virological failure of first line antiretroviral therapy and is associated with
- 436 compensatory mutation L74I. *Journal of Infectious Diseases* (2019).
- 437 42 Naldini, L., Blomer, U., Gage, F. H., Trono, D. & Verma, I. M. Efficient transfer, integration, and
- sustained long-term expression of the transgene in adult rat brains injected with a lentiviral
- 439 vector. *Proc Natl Acad Sci U S A* **93**, 11382-11388, doi:10.1073/pnas.93.21.11382 (1996).
- 440 43 Gupta, R. K. et al. Full length HIV-1 gag determines protease inhibitor susceptibility within in
- 441 vitro assays. *AIDS* **24**, 1651 (2010).
- 442 44 Vermeire, J. et al. Quantification of reverse transcriptase activity by real-time PCR as a fast and
- accurate method for titration of HIV, lenti- and retroviral vectors. *PloS one* **7**, e50859-e50859,
- 444 doi:10.1371/journal.pone.0050859 (2012).

- Mlcochova, P. et al. Combined point of care nucleic acid and antibody testing for SARS-CoV-2 following of D614G Spike Cell 100099, emergence Variant. Rep Med, doi:10.1016/j.xcrm.2020.100099 (2020).
- Seow, J. *et al.* Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol* **5**, 1598-1607, doi:10.1038/s41564-020-00813-8 (2020).

Figure legends

Figure 1. Analysis of 23 Patient derived whole SARS-CoV-2 genome sequences in context of local sequences and other cases of chronic SARS-CoV-2 shedding. Circularised maximum-likelihood phylogenetic tree rooted on the Wuhan-Hu-1 reference sequence, showing a subset of 250 local SARS-CoV-2 genomes from GISAID. This diagram highlights significant diversity of the case patient (green) compared to three other local patients with prolonged shedding (blue, red and purple sequences). All "United Kingdom / English" SARS-CoV-2 genomes were downloaded from the GISAID database and a random subset of 250 selected as background.

Figure 2. Whole genome variant trajectories showing amino acids and relationship to treatments. Data based on Illumina short read ultra deep sequencing at 1000x coverage. Variants shown reached a frequency of at least 10% in at least 2 samples. Treatments indicated are convalescent plasma (CP) and Remdesivir (RDV). Variants described in the text are designated by labels using the same colouring as the position in the genome. Variants labelled are represented by dashed lines. A. Variants detected in the patient from days 1-82. *D796H (light blue) is at the same frequency as NSP3 K902N (orange) therefore it is hidden beneath B. Variants detected in the patient from days 82-101.

Figure 3. Longitudinal variant frequencies and phylogenetic relationships for virus populations bearing six Spike (S) mutations A. At baseline, all six S variants (Illumina sequencing) except for Δ H69/V70 were absent (<1% and <20 reads). Approximately two weeks after receiving two units of convalescent plasma (CP), viral populations carrying Δ H69/V70 and

D796H mutants rose to frequencies >80% but decreased significantly four days later. This population was replaced by a population bearing Y200H and T240I, detected in two samples over a period of 6 days. These viral populations were then replaced by virus carrying W64G and P330S mutations in Spike, which both dominated at day 93. Following a 3rd course of remdesivir and an additional unit of convalescent plasma, the ΔH69/V70 and D796H virus population remerged to become the dominant viral strain reaching variant frequencies of >75%. Pairs of mutations arose and disappeared simultaneously indicating linkage on the same viral haplotype. CT values from respiratory samples are indicated on the right y-axis (black dashed line and triangles). Where there were duplicate readings on the same day, to remain consistent, N+T samples were plotted **B.** Maximum likelihood phylogenetic tree of the case patient with day of sampling indicated. Spike mutations defining each of the clades are shown ancestrally on the branches on which they arose. On dates where multiple samples were collect, these are indicated as endotracheal aspirate (ETA) and Nose + throat swabs (N+T).

Figure 4: Spike mutant D796H + Δ H69/V70 infectivity and sensitivity convalescent plasma (CP). A. western blot of virus pellets after centrifugation of supernatants from cells transfected with lentiviral pseudotyping plasmids including Spike protein. Blots are representative of two independent transfections. **B.** Single round Infectivity of luciferase expressing lentivirus pseudotyped with SARS-CoV-2 Spike protein (WT versus mutant) on 293T cells co-transfected with ACE2 and TMPRSS2 plasmids. Infectivity is corrected for reverse transcriptase activity in virus supernatant as measured by real time PCR. Data points represent technical replicates (n=3) with mean and error bars representing standard error of mean; data are representative of two independent experiments **C-E.** convalescent plasma (CP units 1-3) neutralization potency against pseudovirus virus bearing Spike mutants D796H, Δ H69/V70 and D796H + Δ H69/V70. Patient serum was taken at indicated Day (D). Indicated is serum dilution required to inhibit 50% of virus infection (ID50), expressed as fold change relative to WT. Data points represent means of technical replicates and each data point is an independent experiment (n=2-6). Mean of data points in C-G is shown by horizontal bars.

Extended data legends:

Extended Data Figure 1: Clinical time line of events with longitudinal respiratory sample CT values. CT – cycle threshold.

Extended data 2: A. Blood parameters over time in patient case: White cell count (WCC) and lymphocyte counts are expressed as x10³ Cells/mm³. CRP: C reactive protein. B. Assessment of T cell and innate function. Whole blood cytokines were measured in whole blood after 24 hours stimulation either after T-cell stimulation with PHA or anti CD3/IL2 or innate stimulation with LPS. Healthy controls are shown as grey circles (N=15), Patient at d71 and d98 is shown as blue circles or red circles respectively. Cytokine levels are shown as pg/ml stimulation. Mean is shown by line and whiskers representing standard deviation.

Extended Data Figure 3. A. Serum SARS-CoV-2 antibody levels and virus population changes in chronic SARS-CoV-2 infection. Anti SARS-CoV2 IgG antibodies in patient and pre/post convalescent plasma compared to RNA+ Covid19 patients and prepandemic healthy controls: Red, grey and gold: IgG antibodies to SARS-CoV2 nucleocapsid protein (N), trimeric S protein (S) and the receptor binding domain (RBD) were measured by multiplexed particle based flow cytometry (Luminex) in RNA+ COVID-19 patients (N=20, red dots), Pre-pandemic healthy controls (N=20, grey dots) and in the convalescent donor plasma (orange dots); Results are shown as mean fluorescent intensity (MFI) +/- SD. Patient sera over time in blue: Anti SARS-CoV2 IgG to N (blue squares), S (blue circles) and RBD (blue triangles). Timing of CP units is also shown. B. SARS-CoV-2 antibody titres in patient and in convalescent plasma. Measurement of SARS-CoV-2 specific IgG antibody titres in three units of convalescent plasma (CP) by Euroimmun assay.

Extended data 4. Comparison between short-read (Illumina) and long-read single molecule (Oxford Nanopore) sequencing methods for the six observed Spike mutations. Concordance was generally good between the majority of timepoints, however due to large discrepancies in a number of timepoints, we suggest that due to the high base calling error rate, Nanopore is not yet suitable for calling minority variants. As such, all figures in the main paper were produced using Illumina data only. **B. Single genome sequencing (SGS) data from respiratory samples at indicated days.** Indicated are the number of single genomes obtained at each time point with the mutations of interest (identified by deep sequencing). *denominator is 19 as for 2 samples the primer reads were poor quality at amino acid 796 at day 98. Amino acid variant and corresponding nucleotide position: S:W64G = 21752, $S:\Delta69 = 21765-21770$, S:Y200H = 22160, S:T240I = 22281, S:P330S = 22550, S:D795H = 23948

Extended Data Figure 5: Evidence for within-host cladal structure. A. Pairwise distances between samples measured using the all-locus distance metric plotted against pairwise distances in time (measured in days) between samples being collected. Internal distances between samples in the proposed main clade are shown in black, distances between samples in the main clade and samples collected on days 93 and 95 are shown in red, and internal distances between samples collected on days 93 and 95 are shown in green. B. Pairwise distances between samples in the larger clade (black) and between these samples and those collected on days 93 and 95 (red). The median values of the distributions of these values are significantly different according to a Mann Whitney test. C. Pairwise distances between samples in the main clade, once those collected on days 86, 89, 93, 95 have been removed (black) and between these samples and those collected on days 86 and 89 (red). The median values of the distributions of these values are not significantly different at the 5 level according to a Mann Whitney test.

Extended Data Figure 6: A. Close-view maximum-likelihood phylogenetic tree indicating the diversity of the case patient and three other long-term shedders from the local area (red, blue

and purple), compared to recently published sequences from Choi et al (orange) and Avanzato et al (gold). Control patients generally showed limited diversity temporally, though the Choi et al sequences were highly divergent. Environmental samples (patient's call bell, and patient's mobile phone) are indicated. Tree branched have been collapsed where bootstrap support was <60.

B. Highlighter plot indicating nucleotide changes at consensus level in sequential respiratory samples compared to the consensus sequence at first diagnosis of COVID-19. Each row indicates the timepoint the sample was collected (number of days from first positive SARS-CoV-2 RT-PCR). Black dashed lines indicate the RNA-dependent RNA polymerase (RdRp) and Spike regions of the genome. There were few nucleotide substitutions between days 1-54, despite the patient receiving two courses of remdesivir. The first major changes in the spike genome occurred on day 82, following convalescent plasma given on days 63 and 65. The amino acid deletion in S1, Δ H69/V70 is indicated by the black lines. Sites: Endotracheal aspirate (ETA) or Nose/throat swabs (N+T).

Extended Data 7: In vitro infectivity and neutralisation sensitivity of Spike pseudotyped lentiviruses. A. infection of target 293T cells expressing TMPRSS2 and ACE2 receptors using equal amounts of virus as determined by reverse transcriptase activity. Data points represent technical replicates (n=2), with mean shown with error bars representing standard deviation. Data are representative of n=2 independent experiments (n=2). **B.** Representative Inverse dilution plots for Spike variants against convalescent plasma units 1-3. Data points represent mean neutralisation of technical replicates and error bars represent standard error of the mean of replicates. Data are representative of two independent experiments (n=2).

Extended Data Figure 8. A. Neutralization potency of a panel of monoclonal antibodies targeting the RBD is not impacted by Spike mutations D796H or Δ H69/V70. Lentivirus pseudotyped with SARS-CoV-2 Spike protein: WT (D614G background), D796H, Δ H69/V70, D796H+ Δ H69/V70 were produced in 293T cells and used to infect target Hela cells stably expressing ACE2 in the presence of serial dilutions of indicated monoclonal antibodies. Data are

means of technical replicates with error bars representing SD. Data are representative of at least two independent experiments. RBD: receptor binding domain. **B. Classes of RBD binding antibodies and fold changes for Spike mutations D796H or \DeltaH69/V70 are indicated based Bouwer et al. Clusters II, V contain only non-neutralising mAbs, smaller neutralising mAb clusters IV (n=2) and X (n=1) were not tested. Red indicates significant fold changes.**

596597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

591

592

593

594

595

Extended Data 9. Location of Spike mutations ΔH69/Y70 and D796H. A. The SARS-CoV-2 spike trimer (PDB ID: 6xr8) with two protomers represented as surfaces and one protomer represented as a ribbon. The NTD is coloured in light blue, the RBD in light pink, the fusion peptide in dark pink, the HR1 domain in yellow, the CH domain in pale green, and the CD domain in brown. The location of D796 and H69 are indicated by red spheres. The loop connecting D796 to the fusion peptide is coloured magenta to improve visibility. The double grey lines provide orientation relative to the membrane. B. A close-up of the region defined by the box around H69 in panel A. H69 is highlighted in yellow. Residues containing atoms that are within 6 Å of H69 are highlighted in cyan. C. A close-up of the region defined by the box around D796 in panel A. D796 is highlighted in yellow. Residues containing atoms that are within 6 Å of D796 are highlighted in cyan. Hydrogen bonds are indicated by dashed yellow lines. Hydrophobic residues in the vicinity of D796 have been labelled. Y707 is from the neighbouring protomer. D. Global prevalence of selected spike mutations detailed in this paper. All high coverage sequences were downloaded from the GISAID database on 6th January and aligned using MAFFT; as of this date there were 298254 sequences available. The global prevalence of each of the six spike mutations W64G, ΔH69/V70, Y200H, T240I, P330S and D796H were assessed by viewing the multiple sequence alignment in AliView, sorting by the column of interest, and counting the number of mutations.

615616

617

Methods

- Clinical Sample Collection and Next generation sequencing
- Serial samples were collected from the patient periodically from the lower respiratory tract (sputum or endotracheal aspirate), upper respiratory tract (throat and nasal swab), and from

stool. Nucleic acid extraction was done from 500µl of sample with a dilution of MS2 bacteriophage to act as an internal control, using the easyMAG platform (Biomerieux, Marcy-l'Étoile) according to the manufacturers' instructions. All samples were tested for presence of SARS-CoV-2 with a validated one-step RT q-PCR assay developed in conjunction with the Public Health England Clinical Microbiology²². Amplification reaction were all performed on a Rotorgene™ PCR instrument. Samples which generated a CT of ≤36 were considered to be positive.

627

628

629

Sera from recovered patients in the COVIDx study²³ were used for testing of neutralisation activity by SARS-CoV-2 mutants.

630

- 631 SARS-CoV-2 serology by multiplex particle-based flow cytometry (Luminex):
- 632 Recombinant SARS-CoV-2 N, S and RBD were covalently coupled to distinct carboxylated bead
- sets (Luminex; Netherlands) to form a 3-plex and analyzed as previously described (Xiong et al.
- 634 2020). Specific binding was reported as mean fluorescence intensities (MFI).

635

- 636 Whole blood T cell and innate stimulation assay
- Whole blood was diluted 1:5 in RPMI into 96-well F plates (Corning) and activated by single
- 638 stimulation with phytohemagglutinin (PHA; 10 μg/ml; Sigma-Aldrich), or LPS (1 μg/ml, List
- 639 Biochemicals) or by co-stimulating with anti-CD3 (MEM57, Abcam, 200 ng/ml, 1:1000) and IL-2
- 640 (Immunotools, 1430U/ml, 1:1000). Supernatants were taken after 24 hours. Levels (pg/ml) are
- shown for IFNg, IL17, IL2, TNFa, IL6, IL1b and IL10. Cytokines were measured by multiplexed
- 642 particle based Flow cytometry on a Luminex analyzer (Bio-Plex, Bio-Rad, UK) using an R&D
- 643 Systems custom kit (R&D Systems, UK).

- 645 For viral genomic sequencing, total RNA was extracted from samples as described. Samples
- 646 were sequenced using MinION flow cells version 9.4.1 (Oxford Nanopore Technologies)
- 647 following the ARTICnetwork V3 protocol (https://dx.doi.org/10.17504/protocols.io.bbmuik6w)
- 648 and BAM files assembled using the ARTICnetwork assembly pipeline

(https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html). A representative set of 10 sequences were selected and also sequenced using the Illumina MiSeq platform. Amplicons were diluted to 2 ng/μl and 25 μl (50 ng) were used as input for each library preparation reaction. The library preparation used KAPA Hyper Prep kit (Roche) according to manufacturer's instructions. Briefly, amplicons were end-repaired and had A-overhang added; these were then ligated with 15mM of NEXTflex DNA Barcodes (Bio Scientific, Texas, USA). Post-ligation products were cleaned using AMPure beads and eluted in 25 μl. Then, 20 μl were used for library amplification by 5 cycles of PCR. For the negative controls, 1ng was used for ligation-based library preparation. All libraries were assayed using TapeStation (Agilent Technologies, California, USA) to assess fragment size and quantified by QPCR. All libraries were then pooled in equimolar accordingly. Libraries were loaded at 15nM and spiked in 5% PhiX (Illumina, California, USA) and sequenced on one MiSeq 500 cycle using a Miseq Nano v2 with 2x 250 paired-end sequencing. A minimum of ten reads were required for a variant call.

Bioinformatics Processes

For long-read sequencing, genomes were assembled with reference-based assembly and a curated bioinformatics pipeline with 20x minimum coverage across the whole-genome²⁴. For short-read sequencing, FASTQs were downloaded, poor-quality reads were identified and removed, and both Illumina and PHiX adapters were removed using TrimGalore v0.6.6²⁵. Trimmed paired-end reads were mapped to the National Center for Biotechnology Information SARS-CoV-2 reference sequence MN908947.3 using MiniMap2-2.17 with arguments -ax and sr²⁶. BAM files were then sorted and indexed with samtools v1.11 and PCR optical duplicates removed using Picard (http://broadinstitute.github.io/picard). A consensus sequences of nucleic acids with a minimum whole-genome coverage of at least 20× were generated with BCFtools using a 0% majority threshold.

Variant calling

Variant frequencies were validated using custom code as part of the *AnCovMulti* package (github.com/PollockLaboratory/AnCovMulti). The main idea behind this validation was to

identify and remove consistent potential amplification errors and mutability near the end of Illumina reads. Furthermore, stringent filtering was applied to remove biased amplification of early laboratory-induced mutations or very low copy variations.

Filtering consisted of requiring exact initiation at a primer within two bp of the start of a read, a minimum of 247 bp length read, fewer than four well-separated sites divergent from the reference sequence, a maximum insertion size of three nucleotides, a maximum deletion size of 11 bp, and resolution of conflicting signal from different primers.

Single Genome Amplification and sequencing

Viral RNA extracts were reverse transcribed from each sample to sufficiently capture the diversity of the viral population without introducing resampling bias. SuperScript IV (Thermofisher Scientific) and the gene specific primers were used for reverse transcription. Template RNA was degraded with RNAse H (Thermofisher Scientific). All primers used were 'inhouse' primers designed using the multiple sequence alignment of the patient's consensus NGS sequences. Partial Spike (amino acids 21- 800) was amplified as 1 continuous length of DNA (Spike ~ 1.8 kb) by nested PCR. Terminally diluted cDNA was PCR- amplified using Platinum® Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA) so that 30% of reactions were positive²⁷. By Poisson statistics, sequences were deemed ≥80% likely to be derived from HIV-1 single genomes. We obtained between 20–60 single genomes at each sample time point to achieve 90% confidence of detecting variants present at ≥8% of the viral population in vivo^{28,29}. Partial spike amplicons obtained from terminal dilution PCR amplification were Sanger sequenced to form a contiguous sequence using another set of 8 in-house primers. Sanger sequencing was provided by Genewiz UK and manual sequence editing was performed using DNA Dynamo software (Blue Tractor Software Ltd, UK).

Phylogenetic Analysis

All available full-genome SARS-CoV-2 sequences were downloaded from the GISAID database (http://gisaid.org/)³⁰ on 16th December. Duplicate and low-quality sequences (>5% N regions) were removed, leaving a dataset of 212,297 sequences with a length of >29,000bp. All

sequences were sorted by name and only sequences sequenced with United Kingdom / England identifiers were retained. From this dataset, sequences were de-duplicated and where background sequences were required in figures, randomly subsampled using seqtk (https://github.com/lh3/seqtk). All sequences were aligned to the SARS-CoV-2 reference strain MN908947.3, using MAFFT v7.475 with automatic flavour selection And Major SARS-CoV-2 clade memberships were assigned to all sequences using both the Nextclade server v0.9 (https://clades.nextstrain.org/) and Phylogenetic Assignment Of Named Global Outbreak Lineages (pangolin) And Phylogenetic Assignment Of Named Global Outbreak

Maximum likelihood phylogenetic trees were produced using the above curated dataset using IQ-TREE v2.1.2³³. Evolutionary model selection for trees were inferred using ModelFinder³⁴ and trees were estimated using the GTR+F+I model with 1000 ultrafast bootstrap replicates³⁵. All trees were visualised with Figtree v.1.4.4 (http://tree.bio.ed.ac.uk/software/figtree/), rooted on the SARS-CoV-2 reference sequence and nodes arranged in descending order. Nodes with bootstraps values of <50 were collapsed using an in-house script.

In-depth allele frequency variant calling

The SAMFIRE package version 1.06 36 was used to call allele frequency trajectories from BAM file data. Reads were included in this analysis if they had a median PHRED score of at least 30, trimming the ends of reads to achieve this if necessary. Nucleotides were then filtered to have a PHRED score of at least 30; reads with fewer than 30 such reads were discarded. Distances between sequences, accounting for low-frequency variant information, was also conducted using SAMFIRE. The sequence distance metric, described in an earlier paper 37 , combines allele frequencies across the whole genome. Where L is the length of the genome, we define q(t) as a 4 x L element vector describing the frequencies of each of the nucleotides A, C, G, and T at each locus in the viral genome sampled at time t. For any given locus i in the genome we calculate the change in allele frequencies between the times t_1 and t_2 via a generalisation of the Hamming distance

$$d(q_i(t_1), q_i(t_2)) = \frac{1}{2} \sum_{a \in \{A, C, G, T\}} |q_i^a(t_1) - q_i^a(t_2)|$$

where the vertical lines indicate the absolute value of the difference. These statistics were then combined across the genome to generate the pairwise sequence distance metric

$$D(\boldsymbol{q}(t_1), \boldsymbol{q}(t_2)) = \sum_i d(q_i(t_1), q_i(t_2))$$

The Mathematica software package was to conduct a regression analysis of pairwise sequence distances against time, leading to an estimate of a mean rate of within-host sequence evolution. In contrast to the phylogenetic analysis, this approach assumed the samples collected on days 93 and 95 to arise via stochastic emission from a spatially separated subpopulation within the host, leading to a lower inferred rate of viral evolution for the bulk of the viral population.

All variants were indecently validated using custom code as part of the AnCovMulti package, found at https://github.com/PollockLaboratory/AnCovMulti.

- Western blot analysis
 - Forty-eight hours after transfection of cells with plasmid preparations, the culture supernatant was harvested and passed through a 0.45- μ m-pore-size filter to remove cellular debris. The filtrate was centrifuged at 15,000 rpm for 120 min to pellet virions. The pelleted virions were lysed in Laemmli reducing buffer (1 M Tris-HCl [pH 6.8], SDS, 100% glycerol, β -mercaptoethanol, and bromophenol blue). Pelleted virions were subjected to electrophoresis on SDS–4 to 12% bis-Tris protein gels (Thermo Fisher Scientific) under reducing conditions. This was followed by electroblotting onto polyvinylidene difluoride (PVDF) membranes. The SARS-CoV-2 Spike proteins were visualized by a ChemiDoc MP imaging system (Biorad) using anti-Spike S2 (Invitrogen at 1:1000 dilution) and anti-p24 Gag antibodies (NIH AIDS Reagents 1:1000 dilution).

762 **Recombination Detection** 763 All sequences were tested for potential recombination, as this would impact on evolutionary 764 estimates. Potential recombination events were explored with nine algorithms (RDP, MaxChi, 765 SisScan, GeneConv, Bootscan, PhylPro, Chimera, LARD and 3SEQ), implemented in RDP5 with default settings³⁸. To corroborate any findings, ClonalFrameML v1.12³⁹ was also used to infer 766 recombination breakpoints. Neither programs indicated evidence of recombination in our data. 767 768 769 Structural Viewing 770 The Pymol Molecular Graphics System v2.4.0 (https://github.com/schrodinger/pymol-open-771 source/releases) was used to map the location of the four spike mutations of interested onto a SARS-CoV-2 spike structure visualised by Wrobel et al (PDB: 6ZGE)⁴⁰. 772 773 774 Testing of convalescent plasma for antibody titres 775 The Anti-SARS-CoV-2 ELISA (IgG) assay used to test CP for antibody titres was Euroimmun 776 Medizinische Labordiagnostika AG. This indirect ELISA based assay uses a recombinant 777 structural spike 1 (S1) protein of SARS-CoV-2 expressed in the human cell line HEK 293 for the 778 detection of SARS-CoV2 IgG. 779 780 Generation of Spike mutants 781 Amino acid substitutions were introduced into the D614G pCDNA SARS-CoV-2 Spike plasmid 782 as previously described⁴¹ using the QuikChange Lightening Site-Directed Mutagenesis kit, 783 following the manufacturer's instructions (Agilent Technologies, Inc., Santa Clara, CA). 784 785 Pseudotype virus preparation 786 Viral vectors were prepared by transfection of 293T cells by using Fugene HD transfection 787 reagent (Promega). 293T cells were transfected with a mixture of 11ul of Fugene HD, 1µg of pCDNAΔ19Spike-HA, 1ug of p8.91 HIV-1 gag-pol expression vector^{42,43}, and 1.5μg of pCSFLW 788 789 (expressing the firefly luciferase reporter gene with the HIV-1 packaging signal). Viral 790 supernatant was collected at 48 and 72h after transfection, filtered through 0.45um filter and

791 stored at -80°C. The 50% tissue culture infectious dose (TCID50) of SARS-CoV-2 pseudovirus 792 was determined using Steady-Glo Luciferase assay system (Promega). 793 794 Standardisation of virus input by SYBR Green-based product-enhanced PCR assay (SG-PERT) 795 The reverse transcriptase activity of virus preparations was determined by qPCR using a SYBR Green-based product-enhanced PCR assay (SG-PERT) as previously described⁴⁴. Briefly, 10-fold 796 797 dilutions of virus supernatant were lysed in a 1:1 ratio in a 2x lysis solution (made up of 40% 798 glycerol v/v 0.25% Trition X-100 v/v 100mM KCl, RNase inhibitor 0.8 U/ml, TrisHCL 100mM, 799 buffered to pH7.4) for 10 minutes at room temperature. 800 801 12μl of each sample lysate was added to thirteen 13μl of a SYBR Green master mix (containing 802 0.5μM of MS2-RNA Fwd and Rev primers, 3.5pmol/ml of MS2-RNA, and 0.125U/μl of Ribolock 803 RNAse inhibitor and cycled in a QuantStudio. Relative amounts of reverse transcriptase activity 804 were determined as the rate of transcription of bacteriophage MS2 RNA, with absolute RT 805 activity calculated by comparing the relative amounts of RT to an RT standard of known activity. 806 807 Serum/plasma pseudotype neutralization assay 808 Spike pseudotype assays have been shown to have similar characteristics as neutralisation testing using fully infectious wild type SARS-CoV-2⁸. Virus neutralisation assays were performed 809 810 on 293T cell transiently transfected with ACE2 and TMPRSS2 using SARS-CoV-2 Spike pseudotyped virus expressing luciferase⁴⁵. Pseudotyped virus was incubated with serial dilution 811 812 of heat inactivated human serum samples or convalescent plasma in duplicate for 1h at 37°C. 813 Virus and cell only controls were also included. Then, freshly trypsinized 293T ACE2/TMPRSS2 814 expressing cells were added to each well. Following 48h incubation in a 5% CO2 environment at 815 37°C, the luminescence was measured using Steady-Glo Luciferase assay system (Promega). 816 817 mAb pseudotype neutralisation assay

Virus neutralisation assays were performed on HeLa cells stably expressing ACE2 and using

SARS-CoV-2 Spike pseudotyped virus expressing luciferase as previously described⁴⁶.

818

Pseudotyped virus was incubated with serial dilution of purified mAbs⁹ in duplicate for 1h at 820 821 37°C. Then, freshly trypsinized HeLa ACE2- expressing cells were added to each well. Following 822 48h incubation in a 5% CO₂ environment at 37°C, the luminescence was measured using Bright-823 Glo Luciferase assay system (Promega) and neutralization calculated relative to virus only 824 controls. IC50 values were calculated in GraphPad Prism. 826

825

Data Availability

- 827 Long-read sequencing data that support the findings of this study have been deposited in the
- NCBI SRA database with the accession codes SAMN16976824 SAMN16976846 under 828
- 829 BioProject PRJNA682013 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA682013). Short reads
- 830 and data used to construct figures were deposited at https://github.com/Steven-
- 831 Kemp/sequence files. All data are also available from the corresponding author.

832

833

Code Availability

- 834 The SAMFIRE package Version 1.06 was used for filtering and calling variants from the Illumina
- 835 data. It is available at https://github.com/cjri/samfire/ for review. Additional code was used to
- 836 validate the variant frequencies and can be found at
- 837 https://github.com/PollockLaboratory/AnCovMulti.

838

839

The CITIID-NIHR BioResource COVID-19 Collaboration

840 **Principal Investigators**

- Stephen Baker^{2, 3}, Gordon Dougan^{2, 3}, Christoph Hess^{2,3,26,27}, Nathalie Kingston^{20, 12}, Paul J. Lehner^{2, 3}, Paul 841
- 842 A. Lyons^{2,3}, Nicholas J. Matheson^{2,3}, Willem H. Owehand²⁰, Caroline Saunders¹⁹, Charlotte
- Summers^{,3,24,25,28}, James E.D. Thaventhiran^{2,3,22}, Mark Toshner^{3,24,25}, Michael P. Weekes² 843

844 845

CRF and Volunteer Research Nurses

- Ashlea Bucke¹⁹, Jo Calder¹⁹, Laura Canna¹⁹, Jason Domingo¹⁹, Anne Elmer¹⁹, Stewart Fuller¹⁹, Julie 846
- Harris⁴¹, Sarah Hewitt¹⁹, Jane Kennet¹⁹, Sherly Jose¹⁹, Jenny Kourampa¹⁹, Anne Meadows¹⁹, Criona 847
- O'Brien⁴¹, Jane Price¹⁹, Cherry Publico¹⁹, Rebecca Rastall¹⁹, Carla Ribeiro¹⁹, Jane Rowlands¹⁹, Valentina 848
- 849 Ruffolo¹⁹, Hugo Tordesillas¹⁹

850

851

Sample Logistics

- 852 Ben Bullman², Benjamin J. Dunmore³, Stuart Fawke³⁰, Stefan Gräf ^{3,12,20}, Josh Hodgson³, Christopher
- Huang³, Kelvin Hunter^{2, 3}, Emma Jones²⁹, Ekaterina Legchenko³, Cecilia Matara³, Jennifer Martin³,
- Federica Mescia^{2, 3}, Ciara O'Donnell³, Linda Pointon³, Nicole Pond^{2, 3}, Joy Shih³, Rachel Sutcliffe³, Tobias
- Tilly³, Carmen Treacy³, Zhen Tong³, Jennifer Wood³, Marta Wylot³⁶,

Sample Processing and Data Acquisition

- Laura Bergamaschi^{2, 3}, Ariana Betancourt^{2, 3}, Georgie Bower^{2, 3}, Chiara Cossetti^{2, 3}, Aloka De Sa³, Madeline
- 859 Epping^{2, 3}, Stuart Fawke³², Nick Gleadall²⁰, Richard Grenfell³¹, Andrew Hinch^{2,3}, Oisin Huhn³², Sarah
- Jackson³, Isobel Jarvis³, Daniel Lewis³, Joe Marsden³, Francesca Nice³⁹, Georgina Okecha³, Ommar
- Omarjee³, Marianne Perera³, Nathan Richoz³, Veronika Romashova^{2,3}, Natalia Savinykh Yarkoni³, Rahul
- Sharma³, Luca Stefanucci²⁰, Jonathan Stephens²⁰, Mateusz Strezlecki³¹, Lori Turner^{2, 3},

863864

Clinical Data Collection

- Eckart M.D.D. De Bie³, Katherine Bunclark³, Masa Josipovic⁴⁰, Michael Mackay³, Federica Mescia^{2,3}, Alice
- Michael²⁵, Sabrina Rossi³⁵, Mayurun Selvan³, Sarah Spencer¹⁵, Cissy Yong³⁵

867868

Royal Papworth Hospital ICU

Ali Ansaripour²⁵, Alice Michael²⁵, Lucy Mwaura²⁵, Caroline Patterson²⁵, Gary Polwarth²⁵

870871

Addenbrooke's Hospital ICU

Petra Polgarova²⁸, Giovanni di Stefano²⁸

873874

Cambridge and Peterborough Foundation Trust

875 Codie Fahey³⁴, Rachel Michel³⁴

876877

ANPC and Centre for Molecular Medicine and Innovative Therapeutics

878

Sze-How Bong²¹, Jerome D. Coudert³³, Elaine Holmes³⁷

879880881

NIHR BioResource

- John Allison^{20,12}, Helen Butcher^{12,38}, Daniela Caputo^{12,38}, Debbie Clapham-Riley^{12,38}, Eleanor Dewhurst^{12,38},
- Anita Furlong^{12,38}, Barbara Graves^{12,38}, Jennifer Gray^{12,38}, Tasmin Ivers^{12,38}, Mary Kasanicki^{12,28}, Emma Le
- Gresley^{12,38}, Rachel Linger^{12,38}, Sarah Meloy^{12,38}, Francesca Muldoon^{12,38}, Nigel Ovington^{12,20}, Sofia
- Papadia^{12,38}, Isabel Phelan^{12,38}, Hannah Stark^{12,38}, Kathleen E Stirrups^{12,20}, Paul Townsend^{12,20}, Neil
- Walker^{12,20}, Jennifer Webster^{12,38}.

- 888
- 19. Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University
 Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
- 20. Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK

- 89321. Australian National Phenome Centre, Murdoch University, Murdoch, Western Australia WA6150, Australia
- 22. MRC Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge CB2 1QR, UK
 - 23. R&D Department, Hycult Biotech, 5405 PD Uden, The Netherlands
 - 24. Heart and Lung Research Institute, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
- 899 25. Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 900 0QQ, UK
- 901 26. Department of Biomedicine, University and University Hospital Basel, 4031Basel, Switzerland
- 902 27. Botnar Research Centre for Child Health (BRCCH) University Basel & ETH Zurich, 4058 Basel, 903 Switzerland
 - 28. Addenbrooke's Hospital, Cambridge CB2 0QQ, UK

898

904

905

906

907

908

909

910

913 914

915

916917

921

922

923

924

925

926

929930

931932

933

- 29. Department of Veterinary Medicine, Madingley Road, Cambridge, CB3 0ES, UK
- 30. Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge CB2 0XY, UK
 - 31. Cancer Research UK, Cambridge Institute, University of Cambridge CB2 ORE, UK
 - 32. Department of Obstetrics & Gynaecology, The Rosie Maternity Hospital, Robinson Way, Cambridge CB2 0SW, UK
- 911 33. Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch 912 University, Perth, WA, Australia
 - 34. Cambridge and Peterborough Foundation Trust, Fulbourn Hospital, Fulbourn, Cambridge CB21 5EF, UK
 - 35. Department of Surgery, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
- 918 36. Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, UK
- 37. Centre of Computational and Systems Medicine, Health Futures Institute, Murdoch University,
 Harry Perkins Building, Perth, WA 6150, Australia
 - 38. Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
 - Cancer Molecular Diagnostics Laboratory, Department of Oncology, University of Cambridge,
 Cambridge CB2 0AH, UK
 - 40. Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK
- 927 41. Department of Paediatrics, University of Cambridge, Cambridge Biomedical Campus, Cambridge,
 928 CB2 0QQ, UK

The COVID-62 Genomics UK (COG-UK) Consortium. https://www.cogconsortium.uk

Funding acquisition, Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, Software and analysis tools, and Visualisation:

934 Samuel C Robson 54. 935 936 Funding acquisition, Leadership and supervision, Metadata curation, Project administration, Samples 937 and logistics, Sequencing and analysis, and Software and analysis tools: Nicholas J Loman 82 and Thomas R Connor 51, 110. 938 939 940 Leadership and supervision, Metadata curation, Project administration, Samples and logistics, 941 Sequencing and analysis, Software and analysis tools, and Visualisation: Tanya Golubchik 46. 942 943 944 Funding acquisition, Metadata curation, Samples and logistics, Sequencing and analysis, Software and 945 analysis tools, and Visualisation: 946 Rocio T Martinez Nunez 83. 947 948 Funding acquisition, Leadership and supervision, Metadata curation, Project administration, and 949 Samples and logistics: Catherine Ludden 129. 950 951 952 Funding acquisition, Leadership and supervision, Metadata curation, Samples and logistics, and 953 Sequencing and analysis: Sally Corden ¹¹⁰. 954 955 956 Funding acquisition, Leadership and supervision, Project administration, Samples and logistics, and 957 Sequencing and analysis: Ian Johnston ¹⁴⁰ and David Bonsall ⁴⁶. 958 959 960 Funding acquisition, Leadership and supervision, Sequencing and analysis, Software and analysis tools, and Visualisation: 961 Colin P Smith 128 and Ali R Awan 69. 962 963 964 Funding acquisition, Samples and logistics, Sequencing and analysis, Software and analysis tools, and 965 **Visualisation:** Giselda Bucca 128. 966 967 968 Leadership and supervision, Metadata curation, Project administration, Samples and logistics, and 969 Sequencing and analysis: M. Estee Torok ^{63, 142}. 970 971 972 Leadership and supervision, Metadata curation, Project administration, Samples and logistics, and 973 **Visualisation:** 974 Kordo Saeed 122, 151 and Jacqui A Prieto 124, 150. 975 976 Leadership and supervision, Metadata curation, Project administration, Sequencing and analysis, and 977 Software and analysis tools: David K Jackson ¹⁴⁰. 978 979

Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and

980

981

Software and analysis tools:

William L Hamilton 63. 982 983 984 Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and 985 Luke B Snell 52. 986 987 988 Funding acquisition, Leadership and supervision, Metadata curation, and Samples and logistics: 989 Catherine Moore ¹¹⁰. 990 991 Funding acquisition, Leadership and supervision, Project administration, and Samples and logistics: Ewan M Harrison 129,140. 992 993 994 Leadership and supervision, Metadata curation, Project administration, and Samples and logistics: 995 Sonia Goncalves 140. 996 997 Leadership and supervision, Metadata curation, Samples and logistics, and Sequencing and analysis: Derek J Fairley 44, 113, Matthew W Loose 59 and Joanne Watkins 110. 998 999 1000 Leadership and supervision, Metadata curation, Samples and logistics, and Software and analysis 1001 tools: 1002 Rich Livett ¹⁴⁰. 1003 1004 Leadership and supervision, Metadata curation, Samples and logistics, and Visualisation: Samuel Moses 66, 147. 1005 1006 1007 Leadership and supervision, Metadata curation, Sequencing and analysis, and Software and analysis 1008 tools: Roberto Amato ¹⁴⁰, Sam Nicholls ⁸² and Matthew Bull ¹¹⁰. 1009 1010 1011 Leadership and supervision, Project administration, Samples and logistics, and Sequencing and 1012 analysis: Darren L Smith 78, 99, 146. 1013 1014 1015 Leadership and supervision, Sequencing and analysis, Software and analysis tools, and Visualisation: Jeff Barrett 140, David M Aanensen 55, 155. 1016 1017 1018 Metadata curation, Project administration, Samples and logistics, and Sequencing and analysis: Martin D Curran 106, Surendra Parmar 106, Dinesh Aggarwal 136, 140, 105 and James G Shepherd 89. 1019 1020 1021 Metadata curation, Project administration, Sequencing and analysis, and Software and analysis tools: 1022 Matthew D Parker 134. 1023 1024 Metadata curation, Samples and logistics, Sequencing and analysis, and Visualisation: Sharon Glaysher ¹⁰². 1025 1026 1027 Metadata curation, Sequencing and analysis, Software and analysis tools, and Visualisation: Matthew Bashton 78,99, Anthony P Underwood 55,155, Nicole Pacchiarini 110 and Katie F Loveson 118. 1028 1029

1030 1031	Project administration, Sequencing and analysis, Software and analysis tools, and Visualisation: Alessandro M Carabelli 129.
1032	
1033	Funding acquisition, Leadership and supervision, and Metadata curation:
1034	Kate E Templeton ^{94, 131} .
1035	
1036	Funding acquisition, Leadership and supervision, and Project administration:
1037	Cordelia F Langford ¹⁴⁰ , John Sillitoe ¹⁴⁰ , Thushan I de Silva ¹³⁴ and Dennis Wang ¹³⁴ .
1038	
1039	Funding acquisition, Leadership and supervision, and Sequencing and analysis:
1040	Dominic Kwiatkowski ^{140, 148} , Andrew Rambaut ¹³¹ , Justin O'Grady ^{111, 130} and Simon Cottrell ¹¹⁰ .
1041	,
1042	Leadership and supervision, Metadata curation, and Sequencing and analysis:
1043	Matthew T.G. Holden ¹⁰⁹ and Emma C Thomson ⁸⁹ .
1044	
1045	Leadership and supervision, Project administration, and Samples and logistics:
1046	Husam Osman ^{77, 105} , Monique Andersson ¹⁰⁰ , Anoop J Chauhan ¹⁰² and Mohammed O Hassan-Ibrahim ⁴⁷ .
1047	, , , , , , , , , , ,
1048	Leadership and supervision, Project administration, and Sequencing and analysis:
1049	Mara Lawniczak ¹⁴⁰ .
1050	Mara Lawring Lawring Lawrence Control of the Contro
1051	Leadership and supervision, Samples and logistics, and Sequencing and analysis:
1052	Alex Alderton ¹⁴⁰ , Meera Chand ¹⁰⁷ , Chrystala Constantinidou ¹³⁵ , Meera Unnikrishnan ¹³⁵ , Alistair C Darby
1053	133, Julian A Hiscox 133 and Steve Paterson 133.
1054	, sandin i i i i i i i i i i i i i i i i i i
1055	Leadership and supervision, Sequencing and analysis, and Software and analysis tools:
1056	Inigo Martincorena ¹⁴⁰ , David L Robertson ⁸⁹ , Erik M Volz ⁸⁰ , Andrew J Page ¹¹¹ and Oliver G Pybus ⁶⁴ .
1057	ingo maransorena , pama e nobertson , em more o , maren o rage ana onver o , your
1058	Leadership and supervision, Sequencing and analysis, and Visualisation:
1059	Andrew R Bassett ¹⁴⁰ .
1060	
1061	Metadata curation, Project administration, and Samples and logistics:
1062	Cristina V Ariani ¹⁴⁰ , Michael H Spencer Chapman ^{129, 140} , Kathy K Li ⁸⁹ , Rajiv N Shah ⁸⁹ , Natasha G
1063	Jesudason ⁸⁹ and Yusri Taha ⁹¹ .
1064	
1065	Metadata curation, Project administration, and Sequencing and analysis:
1066	Martin P McHugh 94 and Rebecca Dewar 94.
1067	Water Wender and Resected Sewar .
1068	Metadata curation, Samples and logistics, and Sequencing and analysis:
1069	Aminu S Jahun ⁶⁵ , Claire McMurray ⁸² , Sarojini Pandey ¹²⁵ , James P McKenna ⁴⁴ , Andrew Nelson ^{99, 146} ,
1070	Gregory R Young ^{78, 99} , Clare M McCann ^{99, 146} and Scott Elliott ¹⁰² .
1071	dregory it roung , clare in integral and scott Emoti.
1071	Metadata curation, Samples and logistics, and Visualisation:
1072	Hannah Lowe ⁶⁶ .
1073	Haiman Lowe .
1074	Metadata curation, Sequencing and analysis, and Software and analysis tools:
1075	Ben Temperton ¹³² , Sunando Roy ¹²³ , Anna Price ⁵¹ , Sara Rey ¹¹⁰ and Matthew Wyles ¹³⁴ .
10/0	ben reimperton , bundando noy , mina i nec , bura ney and matthew wyies .

```
1078
           Metadata curation, Sequencing and analysis, and Visualisation:
           Stefan Rooke <sup>131</sup> and Sharif Shaaban <sup>109</sup>.
1079
1080
1081
           Project administration, Samples and logistics, Sequencing and analysis:
           Mariateresa de Cesare 139.
1082
1083
1084
           Project administration, Samples and logistics, and Software and analysis tools:
1085
           Laura Letchford 140.
1086
1087
           Project administration, Samples and logistics, and Visualisation:
           Siona Silveira <sup>122</sup>, Emanuela Pelosi <sup>122</sup> and Eleri Wilson-Davies <sup>122</sup>.
1088
1089
1090
           Samples and logistics, Sequencing and analysis, and Software and analysis tools:
1091
           Myra Hosmillo 65.
1092
1093
           Sequencing and analysis, Software and analysis tools, and Visualisation:
           Áine O'Toole 131, Andrew R Hesketh 128, Richard Stark 135, Louis du Plessis 64, Chris Ruis 129, Helen Adams 45
1094
           and Yann Bourgeois 117.
1095
1096
1097
           Funding acquisition, and Leadership and supervision:
           Stephen L Michell <sup>132</sup>, Dimitris Gramatopoulos <sup>125</sup>, <sup>153</sup>, Jonathan Edgeworth <sup>53</sup>, Judith Breuer <sup>71, 123</sup>, John A
1098
           Todd <sup>139</sup> and Christophe Fraser <sup>46</sup>.
1099
1100
1101
           Funding acquisition, and Project administration:
           David Buck <sup>139</sup> and Michaela John <sup>50</sup>.
1102
1103
1104
           Leadership and supervision, and Metadata curation:
           Gemma L Kay 111.
1105
1106
1107
           Leadership and supervision, and Project administration:
           Steve Palmer 140, Sharon J Peacock 129, 105 and David Heyburn 110.
1108
1109
1110
           Leadership and supervision, and Samples and logistics:
           Danni Weldon <sup>140</sup>, Esther Robinson <sup>105, 77</sup>, Alan McNally <sup>82, 127</sup>, Peter Muir <sup>105</sup>, Ian B Vipond <sup>105</sup>, John BoYes
1111
           <sup>70</sup>, Venkat Sivaprakasam <sup>87</sup>, Tranprit Salluja <sup>116</sup>, Samir Dervisevic <sup>95</sup> and Emma J Meader <sup>95</sup>.
1112
1113
1114
           Leadership and supervision, and Sequencing and analysis:
           Naomi R Park <sup>140</sup>, Karen Oliver <sup>140</sup>, Aaron R Jeffries <sup>132</sup>, Sascha Ott <sup>135</sup>, Ana da Silva Filipe <sup>89</sup>, David A Simpson <sup>113</sup> and Chris Williams <sup>110</sup>.
1115
1116
1117
1118
           Leadership and supervision, and Visualisation:
           Jane AH Masoli 114, 132.
1119
1120
1121
           Metadata curation, and Samples and logistics:
           Bridget A Knight <sup>114, 132</sup>, Christopher R Jones <sup>114, 132</sup>, Cherian Koshy <sup>42</sup>, Amy Ash <sup>42</sup>, Anna Casey <sup>112</sup>, Andrew Bosworth <sup>105, 77</sup>, Liz Ratcliffe <sup>112</sup>, Li Xu-McCrae <sup>77</sup>, Hannah M Pymont <sup>105</sup>, Stephanie Hutchings <sup>105</sup>, Lisa Berry
1122
1123
           125, Katie Jones 125, Fenella Halstead 87, Thomas Davis 62, Christopher Holmes 57, Miren Iturriza-Gomara 133,
1124
           Anita O Lucaci 133, Paul Anthony Randell 79, 145, Alison Cox 79, 145, Pinglawathee Madona 79, 145, Kathryn Ann
1125
```

Harris ⁷¹, Julianne Rose Brown ⁷¹, Tabitha W Mahungu ¹¹⁵, Dianne Irish-Tavares ¹¹⁵, Tanzina Haque ¹¹⁵, Jennifer Hart ¹¹⁵, Eric Witele ¹¹⁵, Melisa Louise Fenton ¹¹⁶, Steven Liggett ¹²⁰, Clive Graham ⁹⁷, Emma Swindells ⁹⁸, Jennifer Collins ⁹¹, Gary Eltringham ⁹¹, Sharon Campbell ⁵⁸, Patrick C McClure ¹³⁸, Gemma Clark ⁵⁶, Tim J Sloan ¹⁰¹, Carl Jones ⁵⁶ and Jessica Lynch ⁴³, ¹⁵².

Metadata curation, and Sequencing and analysis:

Ben Warne ⁴⁹, Steven Leonard ¹⁴⁰, Jillian Durham ¹⁴⁰, Thomas Williams ¹³¹, Sam T Haldenby ¹³³, Nathaniel Storey ⁷¹, Nabil-Fareed Alikhan ¹¹¹, Nadine Holmes ⁵⁹, Christopher Moore ⁵⁹, Matthew Carlile ⁵⁹, Malorie Perry ¹¹⁰, Noel Craine ¹¹⁰, Ronan A Lyons ¹²¹, Angela H Beckett ⁵⁴, Salman Goudarzi ¹¹⁸, Christopher Fearn ¹¹⁸, Kate Cook ¹¹⁸, Hannah Dent ¹¹⁸ and Hannah Paul ¹¹⁸.

Metadata curation, and Software and analysis tools:

Robert Davies 140.

Project administration, and Samples and logistics:

Beth Blane ¹²⁹, Sophia T Girgis ¹²⁹, Mathew A Beale ¹⁴⁰, Katherine L Bellis ^{140, 129}, Matthew J Dorman ¹⁴⁰, Eleanor Drury ¹⁴⁰, Leanne Kane ¹⁴⁰, Sally Kay ¹⁴⁰, Samantha McGuigan ¹⁴⁰, Rachel Nelson ¹⁴⁰, Liam Prestwood ¹⁴⁰, Shavanthi Rajatileka ¹⁴⁰, Rahul Batra ⁵³, Rachel J Williams ¹²³, Mark Kristiansen ¹²³, Angie Green ¹³⁹, Anita Justice ¹⁰⁰, Adhyana I.K Mahanama ^{122, 143} and Buddhini Samaraweera ^{122, 143}.

Project administration, and Sequencing and analysis:

Nazreen F Hadjirin ¹²⁹ and Joshua Quick ⁸².

Project administration, and Software and analysis tools:

Radoslaw Poplawski 82.

Samples and logistics, and Sequencing and analysis:

Leanne M Kermack ¹²⁹, Nicola Reynolds ⁴⁸, Grant Hall ⁶⁵, Yasmin Chaudhry ⁶⁵, Malte L Pinckert ⁶⁵, Iliana Georgana ⁶⁵, Robin J Moll ¹⁴⁰, Alicia Thornton ¹⁰⁷, Richard Myers ¹⁰⁷, Joanne Stockton ⁸², Charlotte A Williams ¹²³, Wen C Yew ⁹⁹, Alexander J Trotter ¹¹¹, Amy Trebes ¹³⁹, George MacIntyre-Cockett ¹³⁹, Alec Birchley ¹¹⁰, Alexander Adams ¹¹⁰, Amy Plimmer ¹¹⁰, Bree Gatica-Wilcox ¹¹⁰, Caoimhe McKerr ¹¹⁰, Ember Hilvers ¹¹⁰, Hannah Jones ¹¹⁰, Hibo Asad ¹¹⁰, Jason Coombes ¹¹⁰, Johnathan M Evans ¹¹⁰, Laia Fina ¹¹⁰, Lauren Gilbert ¹¹⁰, Lee Graham ¹¹⁰, Michelle Cronin ¹¹⁰, Sara Kumziene-SummerhaYes ¹¹⁰, Sarah Taylor ¹¹⁰, Sophie Jones ¹¹⁰, Danielle C Groves ¹³⁴, Peijun Zhang ¹³⁴, Marta Gallis ¹³⁴ and Stavroula F Louka ¹³⁴.

Samples and logistics, and Software and analysis tools:

Igor Starinskij 89.

Sequencing and analysis, and Software and analysis tools:

Chris Jackson 88, Marina Gourtovaia 140, Gerry Tonkin-Hill 140, Kevin Lewis 140, Jaime M Tovar-Corona 140, Keith James ¹⁴⁰, Laura Baxter ¹³⁵, Mohammad T. Alam ¹³⁵, Richard J Orton ⁸⁹, Joseph Hughes ⁸⁹, Sreenu Vattipally ⁸⁹, Manon Ragonnet-Cronin ⁸⁰, Fabricia F. Nascimento ⁸⁰, David Jorgensen ⁸⁰, Olivia Boyd ⁸⁰, Lily Geidelberg ⁸⁰, Alex E Zarebski ⁶⁴, Jayna Raghwani ⁶⁴, Moritz UG Kraemer ⁶⁴, Joel Southgate ^{51, 110}, Benjamin B Lindsey ¹³⁴ and Timothy M Freeman ¹³⁴.

Software and analysis tools, and Visualisation:

Jon-Paul Keatley ¹⁴⁰, Joshua B Singer ⁸⁹, Leonardo de Oliveira Martins ¹¹¹, Corin A Yeats ⁵⁵, Khalil Abudahab ⁵⁵, ¹⁵⁵, Ben EW Taylor ⁵⁵, ¹⁵⁵ and Mirko Menegazzo ⁵⁵.

Leadership and supervision:

John Danesh ¹⁴⁰, Wendy Hogsden ⁸⁷, Sahar Eldirdiri ⁶², Anita Kenyon ⁶², Jenifer Mason ⁸⁴, Trevor I Robinson ⁸⁴, Alison Holmes ⁷⁹, ¹⁴⁴, James Price ⁷⁹, ¹⁴⁴, John A Hartley ¹²³, Tanya Curran ⁴⁴, Alison E Mather ¹¹¹, Giri Shankar ¹¹⁰, Rachel Jones ¹¹⁰, Robin Howe ¹¹⁰ and Sian Morgan ⁵⁰.

Metadata curation:

Elizabeth Wastenge ⁹⁴, Michael R Chapman ^{75, 129, 140}, Siddharth Mookerjee ^{79, 144}, Rachael Stanley ⁹⁵, Wendy Smith ⁵⁶, Timothy Peto ¹⁰⁰, David Eyre ¹⁰⁰, Derrick Crook ¹⁰⁰, Gabrielle Vernet ⁷⁴, Christine Kitchen ⁵¹, Huw Gulliver ⁵¹, Ian Merrick ⁵¹, Martyn Guest ⁵¹, Robert Munn ⁵¹, Declan T Bradley ¹⁰⁴, ¹¹³ and Tim Wyatt ¹⁰⁴.

Project administration:

Charlotte Beaver ¹⁴⁰, Luke Foulser ¹⁴⁰, Sophie Palmer ¹²⁹, Carol M Churcher ¹²⁹, Ellena Brooks ¹²⁹, Kim S Smith ¹²⁹, Katerina Galai ¹²⁹, Georgina M McManus ¹²⁹, Frances Bolt ^{79, 144}, Francesc Coll ⁶⁰, Lizzie Meadows ¹¹¹, Stephen W Attwood ⁶⁴, Alisha Davies ¹¹⁰, Elen De Lacy ¹¹⁰, Fatima Downing ¹¹⁰, Sue Edwards ¹¹⁰, Garry P Scarlett ¹¹⁷, Sarah Jeremiah ¹²⁴ and Nikki Smith ¹³⁴.

Samples and logistics:

Danielle Leek ¹²⁹, Sushmita Sridhar ¹²⁹, ¹⁴⁰, Sally Forrest ¹²⁹, Claire Cormie ¹²⁹, Harmeet K Gill ¹²⁹, Joana Dias ¹²⁹, Ellen E Higginson ¹²⁹, Mailis Maes ¹²⁹, Jamie Young ¹²⁹, Michelle Wantoch ⁴⁸, Sanger Covid Team (www.sanger.ac.uk/covid-team) ¹⁴⁰, Dorota Jamrozy ¹⁴⁰, Stephanie Lo ¹⁴⁰, Minal Patel ¹⁴⁰, Verity Hill ¹³¹, Claire M Bewshea ¹³², Sian Ellard ^{114, 132}, Cressida Auckland ¹¹⁴, Ian Harrison ¹⁰⁷, Chloe Bishop ¹⁰⁷, Vicki Chalker ¹⁰⁷, Alex Richter ¹²⁶, Andrew Beggs ¹²⁶, Angus Best ¹²⁷, Benita Percival ¹²⁷, Jeremy Mirza ¹²⁷, Oliver Megram ¹²⁷, Megan Mayhew ¹²⁷, Liam Crawford ¹²⁷, Fiona Ashcroft ¹²⁷, Emma Moles-Garcia ¹²⁷, Nicola Cumley ¹²⁷, Richard Hopes ¹⁰⁵, Patawee Asamaphan ⁸⁹, Marc O Niebel ⁸⁹, Rory N Gunson ¹⁴¹, Amanda Bradley ⁹³, Alasdair Maclean ⁹³, Guy Mollett ⁹³, Rachel Blacow ⁹³, Paul Bird ⁵⁷, Thomas Helmer ⁵⁷, Karlie Fallon ⁵⁷, Julian Tang ⁵⁷, Antony D Hale ⁹⁰, Louissa R Macfarlane-Smith ⁹⁰, Katherine L Harper ⁹⁰, Holli Carden 90, Nicholas W Machin 86, 105, Kathryn A Jackson 133, Shazaad S Y Ahmad 86, 105, Ryan P George 86, Lance Turtle ¹³³, Elaine O'Toole ⁸⁴, Joanne Watts ⁸⁴, Cassie Breen ⁸⁴, Angela Cowell ⁸⁴, Adela Alcolea-Medina ^{73, 137}, Themoula Charalampous ⁵³, ⁸³, Amita Patel ⁵², Lisa J Levett ⁷⁶, Judith Heaney ⁷⁶, Aileen Rowan ⁸⁰, Graham P Taylor ⁸⁰, Divya Shah ⁷¹, Laura Atkinson ⁷¹, Jack CD Lee ⁷¹, Adam P Westhorpe ¹²³, Riaz Jannoo ¹²³, Helen L Lowe ¹²³, Angeliki Karamani ¹²³, Leah Ensell ¹²³, Wendy Chatterton ⁷⁶, Monika Pusok ⁷⁶, Ashok Dadrah ¹¹⁶, Amanda Symmonds ¹¹⁶, Graciela Sluga ⁸⁵, Zoltan Molnar ¹¹³, Paul Baker ¹²⁰, Stephen Bonner ¹²⁰, Sarah Essex ¹²⁰, Edward Barton ⁹⁷, Debra Padgett ⁹⁷, Garren Scott ⁹⁷, Jane Greenaway ⁹⁸, Brendan Al Payne ⁹¹, Shirelle Burton-Fanning ⁹¹, Sheila Waugh ⁹¹, Veena Raviprakash ⁵⁸, Nicola Sheriff ⁵⁸, Victoria Blakey 58, Lesley-Anne Williams 58, Jonathan Moore 68, Susanne Stonehouse 68, Louise Smith 96, Rose K Davidson ¹³⁰, Luke Bedford ⁶⁷, Lindsay Coupland ⁹⁵, Victoria Wright ⁵⁹, Joseph G Chappell ¹³⁸, Theocharis Tsoleridis ¹³⁸, Jonathan Ball ¹³⁸, Manjinder Khakh ⁵⁶, Vicki M Fleming ⁵⁶, Michelle M Lister ⁵⁶, Hannah C Howson-Wells ⁵⁶, Louise Berry ⁵⁶, Tim Boswell ⁵⁶, Amelia Joseph ⁵⁶, Iona Willingham ⁵⁶, Nichola Duckworth ¹⁰¹, Sarah Walsh ¹⁰¹, Emma Wise ⁴³, ¹⁵², Nathan Moore ⁴³, ¹⁵², Matilde Mori ⁴³, ¹⁴⁹, ¹⁵², Nick Cortes ⁴³, ¹⁵², Stephen Kidd ⁴³, ¹⁵², Rebecca Williams ⁷⁴, Laura Gifford ¹¹⁰, Kelly Bicknell ¹⁰², Sarah Wyllie ¹⁰², Allyson Lloyd ¹⁰², Robert Impey ¹⁰², Cassandra S Malone ⁴⁷, Benjamin J Cogger ⁴⁷, Nick Levene ¹⁰³, Lynn Monaghan ¹⁰³, Alexander J Keeley ¹³⁴, David G Partridge ¹¹⁹, ¹³⁴, Mohammad Raza ¹¹⁹, ¹³⁴, Cariad Evans ¹¹⁹, ¹³⁴, and Mohammad Raza ¹¹⁹, ¹³⁴ ¹³⁴ and Kate Johnson ^{119, 134}.

Sequencing and analysis:

Emma Betteridge ¹⁴⁰, Ben W Farr ¹⁴⁰, Scott Goodwin ¹⁴⁰, Michael A Quail ¹⁴⁰, Carol Scott ¹⁴⁰, Lesley Shirley 1221 140, Scott AJ Thurston 140, Diana Rajan 140, Iraad F Bronner 140, Louise Aigrain 140, Nicholas M Redshaw 140, Stefanie V Lensing 140, Shane McCarthy 140, Alex Makunin 140, Carlos E Balcazar 131, Michael D Gallagher 131, 131 1222 1223 Kathleen A Williamson ¹³¹, Thomas D Stanton ¹³¹, Michelle L Michelsen ¹³², Joanna Warwick-Dugdale ¹³², 1224 Robin Manley ¹³², Audrey Farbos ¹³², James W Harrison ¹³², Christine M Sambles ¹³², David J Studholme ¹³², Angie Lackenby ¹⁰⁷, Tamyo Mbisa ¹⁰⁷, Steven Platt ¹⁰⁷, Shahjahan Miah ¹⁰⁷, David Bibby ¹⁰⁷, Carmen Manso 1225 1226 Angie Lackenby ¹⁰⁷, Tamyo Mbisa ²⁰⁷, Steven Platt ²⁰⁷, Snahjanan Mian ²⁰⁷, David Bioby ¹⁰⁸, Carmen Maiso ¹⁰⁹, Jonathan Hubb ¹⁰⁷, Gavin Dabrera ¹⁰⁷, Mary Ramsay ¹⁰⁷, Daniel Bradshaw ¹⁰⁷, Ulf Schaefer ¹⁰⁷, Natalie Groves ¹⁰⁷, Eileen Gallagher ¹⁰⁷, David Lee ¹⁰⁷, David Williams ¹⁰⁷, Nicholas Ellaby ¹⁰⁷, Hassan Hartman ¹⁰⁷, Nikos Manesis ¹⁰⁷, Vineet Patel ¹⁰⁷, Juan Ledesma ¹⁰⁸, Katherine A Twohig ¹⁰⁸, Elias Allara ¹⁰⁵, ¹²⁹, Clare Pearson ¹⁰⁵, ¹²⁹, Jeffrey K. J. Cheng ¹³⁵, Hannah E. Bridgewater ¹³⁵, Lucy R. Frost ¹³⁵, Grace Taylor-Joyce ¹³⁵, Paul E Brown ¹³⁵, Lily Tong ⁸⁹, Alice Broos ⁸⁹, Daniel Mair ⁸⁹, Jenna Nichols ⁸⁹, Stephen N Carmichael ⁸⁹, ¹⁰⁰, ¹⁰ 1227 1228 1229 1230 1231 Katherine L Smollett ⁸¹, Kyriaki Nomikou ⁸⁹, Elihu Aranday-Cortes ⁸⁹, Natasha Johnson ⁸⁹, Seema Nickbakhsh ⁸⁹, ¹⁰⁹, Edith E Vamos ¹³³, Margaret Hughes ¹³³, Lucille Rainbow ¹³³, Richard Eccles ¹³³, Charlotte Nelson ¹³³, Mark Whitehead ¹³³, Richard Gregory ¹³³, Matthew Gemmell ¹³³, Claudia Wierzbicki ¹³³, 1232 1233 1234 Hermione J Webster 133, Chloe L Fisher 69, Adrian W Signell 61, Gilberto Betancor 61, Harry D Wilson 61, Gaia 1235 Nebbia ⁵³, Flavia Flaviani ⁷², Alberto C Cerda ¹³⁷, Tammy V Merrill ¹³⁷, Rebekah E Wilson ¹³⁷, Marius Cotic 1236 123, Nadua Bayzid 123, Thomas Thompson 113, Erwan Acheson 113, Steven Rushton 92, Sarah O'Brien 92, David J Baker 111, Steven Rudder 111, Alp Aydin 111, Fei Sang 59, Johnny Debebe 59, Sarah Francois 64, Tetyana I 1237 1238 Vasylyeva ⁶⁴, Marina Escalera Zamudio ⁶⁴, Bernardo Gutierrez ⁶⁴, Angela Marchbank ⁵¹, Joshua Maksimovic ⁵⁰, Karla Spellman ⁵⁰, Kathryn McCluggage ⁵⁰, Mari Morgan ¹¹⁰, Robert Beer ⁵⁰, Safiah Afifi ⁵⁰, 1239 1240 Trudy Workman ⁵¹, William Fuller ⁵¹, Catherine Bresner ⁵¹, Adrienn Angyal ¹³⁴, Luke R Green ¹³⁴, Paul J 1241 Parsons ¹³⁴, Rachel M Tucker ¹³⁴, Rebecca Brown ¹³⁴ and Max Whiteley ¹³⁴. 1242

Software and analysis tools:

James Bonfield ¹⁴⁰, Christoph Puethe ¹⁴⁰, Andrew Whitwham ¹⁴⁰, Jennifier Liddle ¹⁴⁰, Will Rowe ⁸², Igor Siveroni ⁸⁰, Thanh Le-Viet ¹¹¹, and Amy Gaskin ¹¹⁰.

Visualisation:

Rob Johnson 80.

1250 1251


1247 1248


- 42. Barking, Havering and Redbridge University Hospitals NHS Trust, Barking, United Kingdom
- 43. Basingstoke Hospital, Basingstoke, United Kingdom
- 44. Belfast Health & Social Care Trust, Belfast, United Kingdom
- 45. Betsi Cadwaladr University Health Board, Betsi Cadwaladr, United Kingdom
- 46. Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- 47. Brighton and Sussex University Hospitals NHS Trust, Brighton & Sussex, United Kingdom
- 48. Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
- 49. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- 50. Cardiff and Vale University Health Board, Cardiff, United Kingdom
- 51. Cardiff University, Cardiff, United Kingdom
- 52. Centre for Clinical Infection & Diagnostics Research, St. Thomas' Hospital and Kings College London, London, United Kingdom
- 53. Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom


- 54. Centre for Enzyme Innovation, University of Portsmouth (PORT), Portsmouth, United Kingdom
- 55. Centre for Genomic Pathogen Surveillance, University of Oxford, Oxford, United Kingdom
- 56. Clinical Microbiology Department, Queens Medical Centre, Nottingham, United Kingdom
- 57. Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
- 58. County Durham and Darlington NHS Foundation Trust, Durham, United Kingdom
- 59. Deep Seq, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, United Kingdom
- 60. Department of Infection Biology, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom
- 61. Department of Infectious Diseases, King's College London, London, United Kingdom
- 62. Department of Microbiology, Kettering General Hospital, Kettering, United Kingdom
- 63. Departments of Infectious Diseases and Microbiology, Cambridge University Hospitals NHS Foundation Trust; Cambridge, UK, Cambridge, United Kingdom
- 64. Department of Zoology, University of Oxford, Oxford, United Kingdom
- 65. Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
- 66. East Kent Hospitals University NHS Foundation Trust, Kent, United Kingdom
- 67. East Suffolk and North Essex NHS Foundation Trust, Suffolk, United Kingdom
- 68. Gateshead Health NHS Foundation Trust, Gateshead, United Kingdom
- 69. Genomics Innovation Unit, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- 70. Gloucestershire Hospitals NHS Foundation Trust, Gloucester, United Kingdom
- 71. Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
- 72. Guy's and St. Thomas' BRC, London, United Kingdom
- 73. Guy's and St. Thomas' Hospitals, London, United Kingdom
- 74. Hampshire Hospitals NHS Foundation Trust, Hampshire, United Kingdom
- 75. Health Data Research UK Cambridge, Cambridge, United Kingdom
- 76. Health Services Laboratories, London, United Kingdom
- 77. Heartlands Hospital, Birmingham, Birmingham, United Kingdom
- 78. Hub for Biotechnology in the Built Environment, Northumbria University, Northumbria, United Kingdom
- 79. Imperial College Hospitals NHS Trust, London, United Kingdom
- 80. Imperial College London, London, United Kingdom
- 81. Institute of Biodiversity, Animal Health & Comparative Medicine, Glasgow, United Kingdom
- 82. Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom
- 83. King's College London, London, United Kingdom
- 84. Liverpool Clinical Laboratories, Liverpool, United Kingdom
- 85. Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom
- 86. Manchester University NHS Foundation Trust, Manchester, United Kingdom
- 87. Microbiology Department, Wye Valley NHS Trust, Hereford, United Kingdom
- 88. MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom

- 89. MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom
- 90. National Infection Service, PHE and Leeds Teaching Hospitals Trust, Leeds, United Kingdom
- 91. Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom
- 92. Newcastle University, Newcastle, United Kingdom
- 93. NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
- 94. NHS Lothian, Edinburgh, United Kingdom
- 95. Norfolk and Norwich University Hospital, Norfolk, United Kingdom
- 96. Norfolk County Council, Norfolk, United Kingdom
- 97. North Cumbria Integrated Care NHS Foundation Trust, Carlisle, United Kingdom
- 98. North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees, United Kingdom
- 99. Northumbria University, Northumbria, United Kingdom
- 100. Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
- 101. PathLinks, Northern Lincolnshire & Goole NHS Foundation Trust, Lincolnshire, United Kingdom
- 102. Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom
- 103. Princess Alexandra Hospital Microbiology Dept., Harlow, United Kingdom
- 104. Public Health Agency, London, United Kingdom
- 105. Public Health England, London, United Kingdom
- 106. Public Health England, Clinical Microbiology and Public Health Laboratory, Cambridge, United Kingdom
- 107. Public Health England, Colindale, London, United Kingdom
- 108. Public Health England, Colindale, London, United Kingdom
- 109. Public Health Scotland, Glasgow, United Kingdom
- 110. Public Health Wales NHS Trust, Cardiff, United Kingdom
- 111. Quadram Institute Bioscience, Norwich, United Kingdom
- 112. Queen Elizabeth Hospital, Birmingham, United Kingdom
- 113. Queen's University Belfast, Belfast, United Kingdom
- 114. Royal Devon and Exeter NHS Foundation Trust, Devon, United Kingdom
- 115. Royal Free NHS Trust, London, United Kingdom
- 116. Sandwell and West Birmingham NHS Trust, Sandwell, United Kingdom
- 117. School of Biological Sciences, University of Portsmouth (PORT), Portsmouth, United Kingdom
- 118. School of Pharmacy and Biomedical Sciences, University of Portsmouth (PORT), Portsmouth, United Kingdom
- 119. Sheffield Teaching Hospitals, Sheffield, United Kingdom
- 120. South Tees Hospitals NHS Foundation Trust, Newcastle, United Kingdom
- 121. Swansea University, Swansea, United Kingdom
- 122. University Hospitals Southampton NHS Foundation Trust, Southampton, United Kingdom
- 123. University College London, London, United Kingdom
- 124. University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
- 125. University Hospitals Coventry and Warwickshire, Coventry, United Kingdom
- 126. University of Birmingham, Birmingham, United Kingdom
- 127. University of Birmingham Turnkey Laboratory, Birmingham, United Kingdom


- 128. University of Brighton, Brighton, United Kingdom
- 129. University of Cambridge, Cambridge, United Kingdom
- 130. University of East Anglia, East Anglia, United Kingdom
- 131. University of Edinburgh, Edinburgh, United Kingdom
- 132. University of Exeter, Exeter, United Kingdom
- 133. University of Liverpool, Liverpool, United Kingdom
- 134. University of Sheffield, Sheffield, United Kingdom
- 135. University of Warwick, Warwick, United Kingdom
- 136. University of Cambridge, Cambridge, United Kingdom
- 137. Viapath, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust, London, United Kingdom
- 138. Virology, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, United Kingdom
- 139. Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- 140. Wellcome Sanger Institute, London, United Kingdom
- 141. West of Scotland Specialist Virology Centre, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
- 142. Department of Medicine, University of Cambridge, Cambridge, United Kingdom
- 143. Ministry of Health, Colombo, Sri Lanka
- 144. NIHR Health Protection Research Unit in HCAI and AMR, Imperial College London, London, United Kingdom
- 145. North West London Pathology, London, United Kingdom
- 146. NU-OMICS, Northumbria University, Northumbria, United Kingdom
- 147. University of Kent, Kent, United Kingdom
- 148. University of Oxford, Oxford, United Kingdom
- 149. University of Southampton, Southampton, United Kingdom
- 150. University of Southampton School of Health Sciences, Southampton, United Kingdom
- 151. University of Southampton School of Medicine, Southampton, United Kingdom
- 152. University of Surrey, Guildford, United Kingdom
- 153. Warwick Medical School and Institute of Precision Diagnostics, Pathology, UHCW NHS Trust, Warwick, United Kingdom











В

